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ABSTRACT
Neuroinflammatory glial responses have been an increasingly recognized component of
neurodegenerative diseases. Of the various glial subsets within the CNS, microglia come at the
forefront of the neural innate immunity and their dysregulation is fundamental to degenerative
neuropathologies. Agreeing with the oxidative paradigm of aging, both neuronal and glial subsets
undergo prolonged oxidative stress, which is ultimately conducive to cellular senescence,
neuroinflammatory and neurodegenerative changes. Nuclear factor erythroid 2-related factor 2
(Nrf2), the cellular master regulator of redox homeostasis is often deregulated in
neurodegenerative diseases and its transcriptional activation has been a prominent diseasemodifying approach. Glycogen Synthase Kinase 3 (GSK3) is the primary mediator of tau
hyperphosphorylation and aberrant amyloid deposition and dysregulation of its activity is a major
contributor to CNS proteopathy. GSK3 is also associated with the proinflammatory phenotype of
microglia and has been shown to act in concert with NF-κB, a key inflammatory molecule.
Moreover, GSK3 is a negative regulator of Nrf2 and its inhibition is among postulated strategies
of anti-oxidative Nrf2 activation. Only one of the two isoforms of GSK3 (GSK3β) has been
thoroughly studied and mostly its role in proteopathies of neuronal origin has been the focus of
previous research. In this study, we aimed to explore the multimodal disease-modifying utility of
GSK3 beyond neuronal proteopathologies, particularly in microglia, whereby its inhibition was
surmised to simultaneously activate the Nrf2-orchestrated antioxidant response, discourage NFκB-driven inflammatory events, over and above its tried and tested utility in modulating protein
pathology. Furthermore, we aimed to underscore the difference in therapeutic value between the
two GSK3 paralogs by isoform-selective chemical inhibition.
The anti-inflammatory effects of BRD0705 (GSK3α-selective inhibitor), BRD3731 (GSK3βselective inhibitor), and BRD0320 (GSK3α/β inhibitor) were preliminarily determined as a
function of the reductive capacity of each to mitigate LPS-induced proinflammatory activation of
SIM-A9 microglia, as demonstrated by downscaling of the levels of secreted nitrite. Building upon
this, post-treatment downregulation of LPS-elevated mRNA expression of several inflammatory
markers (CD11b, Iba1, iNOS, IL-1β, IL-6, and TNF-α) was evaluated by real-time qPCR.
Transcriptional targets of Nrf2 (HO-1 and Osgin1) were also analyzed by qPCR to determine the
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competency of selective GSK3 inhibition at mediating Nrf2 transcriptional activation.
Additionally, post-treatment concentrations of the secretory proinflammatory cytokines IL-1β, IL6, and TNF-α in supernatant of LPS-stimulated SIM-A9 microglia were estimated by sandwich
ELISA. To deduce whether the regulatory action of the GSK3 inhibitor compounds may be
mediated via the nuclear translocation of NF-κB and Nrf2, nuclear lysates of LPS-stimulated and
GSK3 inhibitor-treated SIM-A9 cells were analyzed for NF-κB and Nrf2 expression by western
immunoblotting. β-catenin was similarly appraised to circumstantiate the projected discrepancy
between BRD0705 (GSK3α inhibitor) and BRD3731 (GSK3β inhibitor) as to their β-catenindestabilizing influence. Finally, to infer whether the counter-inflammatory activity of the GSK3
inhibitor compounds was Nrf2-dependent, DsiRNA-mediated knockdown of Nrf2 was attempted.
The mRNA expression of the Nrf2 target genes HO-1 and Osgin1 as well as the proinflammatory
markers iNOS, IL-1β, IL-6, and TNF-α in LPS-activated SIM-A9 DsiNrf2 cells treated with GSK3
inhibitors was reassessed by real-time qPCR to monitor post-knockdown modulatory trends.

Results from our experiments reveal a superior anti-inflammatory and anti-oxidative efficacy for
GSK3β-selective inhibition, compared to GSK3α-selective and non-selective pan-inhibition,
suggesting that inhibition of GSK3β is more crucial to a significant disease-modifying outcome
than GSK3α; hence use of selective GSK3β inhibitors is likely to be more propitious than nonselective dual inhibitors administered at comparable doses. Not incongruous with the above,
GSK3α-selective inhibition remains a worthy recourse in pro-oncogenic contexts, given its mild
to moderate anti-inflammatory and anti-oxidative potential in addition to its impotency at
activating the tumorigenic β-catenin-driven transcriptional program. Moreover, our results suggest
that the anti-inflammatory effects of GSK3 inhibition is not Nrf2 dependent.
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1. INTRODUCTION AND LITERATURE REVIEW
1.1. Neuroinflammation: what’s in a name?

Neuroinflammation is the inflammatory response occurring in the central nervous system (CNS)
following any number of stimuli, benign or pernicious (DiSabato et al., 2016). Primarily mediated
by CNS-resident glia, inflammation within the brain or spinal cord is fundamentally beneficial and
essential to homeostatic neurophysiology. However, uncontrolled chronic inflammatory responses
are essentially maladaptive and conducive to extensive CNS damage that can very well go as far
as engendering neuronal degeneration (Chitnis & Weiner, 2017; DiSabato et al., 2016).
Physiological changes associated with old age such as cellular senescence and build-up of cellular
debris result in age-linked parainflammation, a chronic inflammatory phenomenon that has been
recognized well enough to receive its own name, “inflammaging” (M. Chen & Xu, 2015; Walker,
2019). A growing body of evidence suggests that neuroinflammation is an integral component of
neurodegenerative diseases (NDs) such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS), and frontotemporal lobar dementia (FTD) (Guzman-Martinez
et al., 2019; H. S. Kwon & Koh, 2020; Ransohoff, 2016). According to a news feature published
in Nature in 2018 (Abbott, 2018), four of eight drug-discovery projects sponsored by the British
Dementia Consortium sought to tackle neuroinflammation. Moreover, several patents relating to
CNS inflammation-targeting pharmaceuticals have been filed and it is anticipated that an upswing
of clinical trials will soon be seen, according to Martin Hofmann-Apitius of the Fraunhofer
Institute, who specializes in pharmaceutical research (Abbott, 2018). It is as early as the 1990s that
inflammation was being linked to neurodegeneration; epidemiological data even showed that
individuals on anti-inflammatory therapy for conditions such as rheumatoid arthritis were less
likely to develop Alzheimer’s disease than was the general population (Chou et al., 2016; Judge et
al., 2017; Newby et al., 2020). According to Streit and associates, “The term neuroinflammation
has come to denote chronic, CNS-specific, inflammation-like glial responses that do not reproduce
the classic characteristics of inflammation in the periphery but that may engender
neurodegenerative events; including plaque formation, dystrophic neurite growth, and excessive
tau phosphorylation” (Streit et al., 2004). As such, neuroinflammation is increasingly becoming
acknowledged as intrinsic to NDs, a group of pathologies that had not been previously thought of
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as essentially inflammatory. Moreover, emerging evidence suggests that neuroinflammation has a
causal role in neurodegenerative pathophysiology (Guzman-Martinez et al., 2019; Morales et al.,
2016). Such departure from classical views was occasioned by a better-informed understanding of
microglial neurobiology and awareness of the fact that the events accompanying microglial
activation rise above the classical notion of “reactive gliosis”, which entails a passive glial
response rather than the “take-charge” role microglia assume and which is inherent to the
activation paradigm hereunder explained. Presently, microglia constitute the focus of
neuroimmunology as corroborated by Graebera and colleagues, who thought that “microglia are
of greatest interest in the context of neuroimmunology” (Manuel B. Graeber et al., 2011), and in
turn, neuroinflammation (Streit et al., 2004).
1.2. Microglia: the brain’s front battalion

Microglia are immunocompetent cells of the monocyte lineage and the resident macrophages of
the CNS (Streit, 2002). Microglia arise from yolk-sac-derived erythromyeloid precursors (EMPs)
during primitive hematopoiesis, as demonstrated by fate-mapping studies (Perdiguero et al., 2015).
EMPs colonize the brain in utero, around 8.5 days post-fertilization in mice and as early as 13
weeks of gestation in humans, before the completion of vasculature arborization and the formation
of the blood-brain barrier (BBB) (Z. Chen & Trapp, 2016; Perdiguero et al., 2015). EMPs then
differentiate into microglia, which maintain their population by self-renewal throughout an
individual’s lifespan (Ajami et al., 2007); such self-maintenance without any hematopoietic input
may suggest that microglia are particularly vulnerable to aging and degeneration (Ginhoux et al.,
2010; Lenz & Nelson, 2018), which has enormous bearing on the thesis of this study. Microglia
make up to 16% of the total cellular population in the CNS in humans and up to 12% in rodents
(Norden & Godbout, 2013).

Microglia, the only true parenchymal macrophages, serve as the front line of defense in the face
of any incursion against the CNS (Q. Li & Barres, 2017). Through a repertoire of specialized
surface receptors, they recognize potential insults to the CNS and initiate an immune response for
the elimination of the causative noxious agent (Yin et al., 2017). Beyond their immunoregulatory
role, microglia are integral to normal development of the CNS and its lifelong maintenance
2

thereafter (Erblich et al., 2011; Hoshiko et al., 2012; Michell-Robinson et al., 2015; Schafer et al.,
2012; Squarzoni et al., 2014; Ueno et al., 2013). During development, microglia keep neurogenesis
in check by phagocytosing neural precursor cells to prevent the overproduction of neurons beyond
the requirement of the cerebral cortex (Cunningham et al., 2013). They also postnatally carry out
synaptic pruning to clear superfluous excitatory synapses (Hong et al., 2016; Paolicelli et al.,
2011). Their housekeeping role also involves synaptic remodeling (Y. Wu et al., 2015),
maintenance of myelin homeostasis (Hagemeyer et al., 2017), and clearing up of debris and dead
cells (Herzog et al., 2019; Neumann et al., 2009; Petersen & Dailey, 2004). Dysregulation of these
housekeeping functions may thus have neurodegenerative implications.

Microglia populate the brain in microdomains forming a mosaic, grid-like network, which makes
them ideally distributed to effectively carry out their functions (Beggs & Salter, 2016). Microglia
have been thought to be idle bystanders in health. This postulation has long been invalidated. In
their “surveillance” state, microglia project numerous ramified and highly motile processes that
constantly extend and retract at a rate of 2.5 μm-1.5 mm/min, continuously sampling their local
microenvironment to monitor for and promptly combat any dyshomeostasis (Nimmerjahn et al.,
2005; Peri & Nüsslein-Volhard, 2008; Svahn et al., 2013). Therefore, the common terminologies
of “resting microglia” or “quiescent microglia” for this microglial subset should be recognized as
misnomers (Hanisch & Kettenmann, 2007; Thompson & Tsirka, 2017). These glial sentinels have
an elaborate sensome, made up of around 100 genes thanks to which, such surveillant role is
possible (Lively & Schlichter, 2018). If and when an aggravating stimulus is encountered,
microglia assume an “activated state”, which is characterized by several phenotypic changes (Leyh
et al., 2021). Activated microglia undergo cytoskeletal rearrangements and exhibit an amoeboid
morphology with a hypertrophic cyton and retracted processes (Doorn et al., 2014). Activated
microglia have also been demonstrated to display multi-nucleated, rod, epithelioid and dystrophic
morphologies (Boche et al., 2013). Microglia have a very low threshold of activation and such
activation occurs within only a few min of exposure to the noxious stimulus (Shinozaki et al.,
2014). Microglial activation is normally transient and the cells revert back to the surveillant state
once the inciting stimulus has been resolved (Perry & Teeling, 2013).

3

A model describing macrophage activation as distinctive polarization states has been adopted over
two decades ago (Mills et al., 2000). Such polarization paradigm recognizes a proinflammatory
state of macrophages that has been labelled “M1” and an anti-inflammatory state known as “M2”
(Yunna et al., 2020). According to this paradigm, proinflammatory M1 macrophages can be
induced by bacterial lipopolysaccharide (LPS), peptidoglycan or interferon-gamma (IFN-γ) (K.
Ma et al., 2019). They exhibit increased expression of integrins (CD11b, CD11c) (Kamphuis et
al., 2016; Ladeby et al., 2005; A Roy et al., 2008), major histocompatibility complex II (MHC-II)
(Jurga et al., 2020), Fc receptors (Okun et al., 2010; Peress et al., 1993; Song et al., 2002, 2004)
as well as co-stimulatory molecules (CD68, CD86, CD36) and are characterized by the production
of nitric oxide through stimulation of inducible nitric oxide synthase (iNOS) (Brown, 2007).
Microglia generate reactive oxygen and nitrogen species in addition to a range of chemokines such
as C-C motif chemokine 22 (CCL22) and proinflammatory cytokines, e.g., tumor necrosis factorα (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) (Akiyama et al., 2000; Varnum &
Ikezu, 2012). M2 macrophages, on the other hand, work to counteract inflammation. They
manifest an upregulation of arginase 1 (ARG1) (Akiyama et al., 2000), produce growth factors
such as colony stimulating factor 1 (CSF1), anti-inflammatory mediators viz. interleukin-4 (IL-4),
interleukin-10 (IL-10) (Lyons et al., 2007; Nolan et al., 2005), found in inflammatory zone 1
(FIZZ1), extracellular matrix-binding lectins, namely chitinase-like protein 3 (Ym1) (Raes,
Baetselier, et al., 2002; Raes, Noël, et al., 2002) and neurotrophic factors like glial cell-derived
neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF). Under the M1/M2
paradigm, microglia are surmised to exist in a neutral M0 state to physiologically maintain a
balance between both activation states. However, in disease, this balance is conjectured to be
skewed, favoring one activation state over the other. That being said, attempts to define a clearcut M1 or M2 signature have failed and, recently, the M1/M2 dichotomy – which may stand in
vitro – has been widely debunked and rejected as way too simplistic to describe a much more
complex and graded spectrum of microglial phenotypes in vivo (Bachiller et al., 2018; Biase et al.,
2017; Keren-Shaul et al., 2017).

To bring the above into perspective, the heterogeneity of microglial phenotypes can be observed
with any single anatomical brain region; even in very close proximity, microglia can show
disparate transcriptomic signatures which weighs in on their functional role and characteristics
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(Bachiller et al., 2018; Jiang-Shieh et al., 2003; C. H. Wu et al., 1997). Such heterogeneity of
activation profiles is especially significant in NDs, where variegation of the transcriptional
landscape proportionally correlate with disease progression (Bachiller et al., 2018). This in vivo
complexity partially derives from the perpetual and reciprocal interaction of microglia with other
components of the CNS (Colton, 2009; D. Morgan et al., 2005). Additionally, M1/M2 assumptions
made about peripheral macrophages may not translate to microglia, given their distinctive
developmental origin and the versatility of their function compared to peripheral macrophages
(Jurga et al., 2020; Q. Li & Barres, 2017). Microglial phenotypes are thus plastic and the use of
the M1/M2 nomenclature will therefore be limited throughout the remainder of the text.

Drawing on the neuroinflammatory nature of dementias, it is worth mentioning that dysregulated
activation of microglia is indeed a common pathological feature of NDs. Even in the early
depictions sketched by Alois Alzheimer, microglia feature abundantly alongside neurons,
proximal to regions were the prototypical plaques and tangles were depicted (M.B. Graeber et al.,
1997; Hemonnot et al., 2019; Stelzmann et al., 1995). Post-mortem reports provided credence to
these early sketches by showing microglia gathering around plaques and in degenerating brain
regions (Hemonnot et al., 2019). Moreover, proinflammatory cytokines were found in the
cerebrospinal fluid of AD patients (X. Chen et al., 2018; Llano et al., 2012).

In the context of their study of AD pathophysiology, Heneka and colleagues found that activated
microglia eliminate remnants of inflammasomes (cytosolic protein oligomers of innate immunity
orchestrating the activation of the inflammatory response) in the form of minuscule lumps
(Venegas et al., 2017). These flecks go on to seed further amyloidopathy, spreading the disease
across the brain. Heneka labelled this phenomenon as “the perfect storm”, given the findings
proving that toxic amyloid-β (Aβ) incites inflammation, which foments the formation of further
toxic Aβ. Surprisingly, knocking out NLR Family Pyrin Domain Containing 3 (NLRP3) – the gene
encoding the NLRP3 protein, a major component of inflammasomes – was neuroprotective in AD
murine models (Heneka et al., 2012).

Therefore, contrary to linear models suggesting precedence of neuroinflammation to neuronal
degeneration – on grounds of its detrimental effects and the disease-spreading capacity of
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microglial cells – and to simple “cause and effect” constructs attesting to the initiation of
neuroinflammation subsequent of neurodegeneration, the chronic nature of neurodegenerative
proteopathies entails intricate feedback loops and complex, bilateral neuron-glia interactions .

Notwithstanding evidence supporting a pathophysiological non-linearity, there still exist other
likewise well-grounded views that support a more directional progress of events. To provide an
instance, one accepted model outlining a sequence of events for AD gives precedence to Aβ
accumulation, which in turn instigates microglial activation (Hickman et al., 2018). Activated
microglia subsequently engender the hyperphosphorylation of tau and the consequent emergence
of neurofibrillary tangles (D. C. Lee et al., 2010; Yoshiyama et al., 2007), which eventually leads
to neurodegeneration and ensuing cognitive impairment (Hickman et al., 2018).

For all the above-outlined, whether microglia should be triggered or subdued for a beneficial
clinical outcome remains debatable. It is true that microglia can go rogue, overreacting to
proteopathic stimuli in desperate attempts to up their game. These subsets overproduce
inflammatory signals, regurgitate phagocytosed toxic proteins that seed new plaques and tangles
and mistakenly flag synapses for destruction, which altogether contribute to furthering
neurodegeneration. Nonetheless, given the heterogeneity of microglial phenotypes, the diverse
roles they play in different stages of disease and the slew of studies showing microglia clearing
away toxic protein forms and protecting neurites from destruction; finetuning the microglial
response and working to enrich innocuous subsets is increasingly being pursued and regarded as
meritorious. As a general framework, while neuroprotective in the earlier stages of disease,
microglia shift to a neurotoxic phenotype as the disease progresses (Onuska, 2020).

1.3. The GSK3/Nrf2/NF-κB signaling network in neuroinflammation
Within a fairly complex signaling circuitry, glycogen synthase kinase 3 (GSK3), nuclear factor
erythroid 2-related factor 2 (Nrf2) and nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) constitute a particularly important regulatory loop in neuroinflammation and NDs
(Bianca Marchetti, 2020). In the context of Parkinson’s disease for instance, one group put forth
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multiple reports suggesting a signaling cooperativity between the Nrf2/ARE pathway and the
Wnt/β-catenin pathway, of which GSK3 is a central regulator. The convergence of these two axes
was recognized as consequential to glial-mediated inflammation, aging and neuronal degeneration
and – when properly regulated – conducive to promoting cellular survival, regenerative and antiaging molecular programs (Harvey & Marchetti, 2014; L’episcopo et al., 2011; L’Episcopo et al.,
2010, 2012, 2013, 2014; B Marchetti & Pluchino, 2013). Crosstalk between GSK3 and NF-κB as
well as NF-κB and Nrf2 has been corroborated and evinced to actively affect cellular inflammatory
programs and modulate degenerative subcellular events. To outline the framework of the study at
hand and present the molecular paradigm after which this work was designed, each of the above
mediators shall be hereunder discussed in detail in relation to the other players.

1.3.1. Nuclear factor erythroid 2-related factor 2 (Nrf2)

Nuclear factor erythroid 2 [NF-E2]-Related Factor 2 (Nfe2l2 or Nrf2) is a basic-region leucine
zipper (bZIP) transcription factor discovered in 1994, belonging to the cap “n” collar (CNC)
subfamily (Moi et al., 1994). Nrf2 is the principal regulator of the cellular response against
oxidative stress by oxidants, electrophiles, and inflammatory agents (Q. Ma, 2013; Silva-Islas &
Maldonado, 2018; Tummala et al., 2016). More than 250 cytoprotective genes are regulated by
Nrf2 (Hayes & Dinkova-Kostova, 2014); these genes encode a myriad of vital enzymes involved
in biotransformation of endo- and xenobiotics, NADPH regeneration, lipid and heme catabolism,
detoxification of reactive oxygen species (ROS), among others (Cuadrado, Manda, et al., 2018;
Tonelli et al., 2018). Beyond its role in regulating antioxidant responses, Nrf2 has also been
reported to modulate mitochondrial bioenergetics (Holmström et al., 2013) and mitigate the
unfolded protein response (Meakin et al., 2014; M. Wang & Kaufman, 2014).

Nrf2 is a multidomain protein comprised of seven Nrf2-ECH homology modules (Neh1–Neh7),
each with distinctive features and functions (Itoh et al., 1999; H. Wang et al., 2013) (Figure 1.1).
The DNA-binding CNC-bZIP domain is represented in the Neh1 module of the protein (Itoh et al.,
1999). The sequence of this domain, particularly its basic region, is evolutionarily conserved,
signifying its importance to the transcriptional activity of Nrf2 (Fuse & Kobayashi, 2017). The
DLG and ETGE motifs, nested within the Neh2 domain, are two other largely conserved stretches
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of the protein (Tong et al., 2006). These motifs are essential for the interaction of Nrf2 with its
primary negative regulator, Kelch-like ECH-associated protein 1 (Keap1) (Itoh et al., 1999;
McMahon et al., 2003; Tong et al., 2006). The Neh2 module also contains seven lysine residues
between the DLG and ETGE motifs, which also have important regulatory roles (D. D. Zhang et
al., 2004). The Neh3 module at the C-terminus, along with Neh4 and Neh5, constitute the
transactivation domains of Nrf2 and cooperatively function to mediate the transcription of its target
genes (Katoh et al., 2001; Nioi et al., 2005). The Neh6 module harbors two serine-rich motifs,
DSGIS and DSAPGS, which play a central role in GSK3-mediated Keap1-independent regulation
of Nrf2 (Chowdhry et al., 2012).

Figure 1.1. Structure of Nrf2 protein. The Nrf2 protein is composed of 7 Nrf2-ECH homolog (Neh) domains (Neh1-Neh7). Both
Neh2 and Neh6 are degron domains. The Neh2 domain is located at the N-terminus of the Nrf2 protein; it harbors the DLG and
ETGE motifs that are recognized by the E3 ligase adaptor, Keap1. The Nrf2-bound Keap1 homodimer presents Nrf2 to the
CUL3/RBX1 complex which ubiquitinates seven lysine residues between the DLG and ETGE motifs (K44, K50, K52, K53, K56,
K64, K68) marking the protein for proteosomal degradation. The Neh6 domain features the DSGIS and DSAPGS motifs which are
recognized by the E3 ligase adaptor β-TrCP and, once bound, the CUL1/RBX1 complex is recruited for ubiquitination of Nrf2 and
its degradation by the proteosome. Nrf2 recognition by β-TrCP requires prior phosphorylation by GSK3β at S344 and S347 residues
(colored in blue) of the DSGIS motif. Neh3, Neh4 and Neh5 are all transactivation domains. The Neh1 module is the DNA-binding
domain; it associates with small Maf proteins and other transcription factors to initiate the transcription of ARE genes. Direct
interaction between the retinoid X receptor and the Neh7 domain mediates the repression of Nrf2 transcriptional activity. Created
with BioRender.com.

The abundance and transcriptional activity of Nrf2 are rigorously regulated on the DNA, RNA and
protein levels. Herein, only regulation by protein stabilization is outlined, given its relevance to
the premise of the proposed work.

Nrf2 is primarily stabilized in the cytoplasm by Keap1, an adaptor for substrates of the E3 ubiquitin
ligase complex, Cullin 3 and RING-box protein 1 (CUL3/RBX1) (A. Kobayashi et al., 2004).
8

Keap1 is a redox sensor and functions as a negative regulator of Nrf2 in absence of electrophilic
stimuli (Cullinan et al., 2004; Furukawa & Xiong, 2005; A. Kobayashi et al., 2004; D. D. Zhang
et al., 2004). In absence of such stimuli, Keap1 binds the DLG and ETGE motifs of Neh2 through
the Kelch motif in its beta propeller domain, whereby Nrf2 is marked for ubiquitination by
CUL3/RBX1 and its proteasomal degradation is subsequently initiated (Baird et al., 2014;
Dinkova-Kostova et al., 2002; Itoh et al., 2003; Levonen et al., 2004). Given the short half-life of
Nrf2 (10-30 min) and its rapid turnover by Keap1, the basal levels of Nrf2 are minimal (Tonelli et
al., 2018). Oxidative stress stimulates the detachment of Keap1 from Nrf2, where reactive
cysteines in the former are particularly sensitive to oxidation by free radicals/electrophiles and
their modification lends to a conformational change of the negative regulator and its dissociation
from Nrf2 (Cuadrado, Manda, et al., 2018; Silva-Islas & Maldonado, 2018; Tonelli et al., 2018;
D. D. Zhang & Hannink, 2003). Consequently, Nrf2 is free to translocate to the nucleus, where it
heterodimerizes with small masculoaponeurotic fibrosarcoma (sMaf) proteins (MafF, MafG and
MafK) (W. Li et al., 2008; Motohashi et al., 2002), binds to the antioxidant response element
(ARE; 5′-TGACXXXGC-3′) within the promoter regions of its target antioxidant genes and
initiates their transcription (Friling et al., 1992; Rushmore et al., 1991; Telakowski-Hopkins et al.,
1988).

An alternative ubiquitination-dependent regulatory mechanism hinges on the phosphorylation of
serine residues within the DSGIS motif of Neh6 by GSK3β, which presents Nrf2 to the substrate
recognition adaptor, β-transducing repeat-containing protein (β-TrCP) (Rada et al., 2011).
CUL1/RBX1 ubiquitin ligase complex is recruited to β-TrCP-bound Nrf2, initiating a Keap1independent mode of Nrf2 proteosomal degradation (Rada et al., 2011). Both canonical and noncanonical Nrf2 regulatory pathways are illustrated in Figure 1.2.
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Figure 1.2. Regulation of Nrf2 activity: A. Canonical Nrf2/ARE pathway: In resting conditions, Nrf2 is kept in the cytosolic
compartment by the homodimeric adaptor protein Keap1, which binds the DLG and the ETGE motifs of the Neh2 domain of
Nrf2. As a result, Nrf2 is recognized by the Cul3/RX1 complex, which ubiquitinates several ubiquitin acceptor lysine residues
in between the Keap1-interfacing motifs, marking Nrf2 for proteosomal degradation. In conditions of oxidative stress, free
radicals or electrophilic agents oxidize reactive cysteine residues within the BTB domain of Keap1, causing its detachment
from Nrf2, which then becomes free to translocate to the nuclear compartment, where it binds sMAF proteins, initiating the
transcription of ARE genes. B. Non-canonical regulation: GSK3β constitutively phosphorylates key serine residues within the
DSGIS motif of the Nrf2 Neh6 module, priming its recognition by β-TrCP. Once bound by β-TrCP, Nrf2 can be ubiquitinated
by the Cul1/RBX1 complex and shipped off to the proteosome for degradation. Inhibition of GSK3β precludes the priming
phosphorylation event that initiates the degradative cascade, ultimately resulting in enhanced nuclear entry. Created with
BioRender.com.
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1.2.1.1. Nrf2 in neuronal degeneration

Dysregulation of Nrf2 has been linked to NDs such as AD, PD, ALS, multiple sclerosis,
Huntington's disease (HD), and Friedreich's ataxia (Dinkova-Kostova et al., 2018; Johnson &
Johnson, 2015; Yang et al., 2015). Generally, chronic and aging-related diseases often entail lowgrade cellular stress (Calder et al., 2017; Sanada et al., 2018), which is distinctly characterized by
the formation of free radicals and ROS as byproducts of cellular processes in the mitochondria,
endoplasmic reticulum and peroxisomes and occurs as a consequence of dysregulated homeostatic
mechanisms (Zuo et al., 2019). At exaggerated levels, these oxidative/electrophilic entities can
seriously damage vital biomolecules (Rahal et al., 2014). Conforming to the oxidative paradigm
of aging, an age-associated exacerbation of cerebral oxidative damage has been recurrently
demonstrated (Kumar et al., 2012; Yamazaki et al., 2015).

A study of the fatal Hutchinson-Gilford progeria syndrome (HGPS), which is essentially a
premature aging condition, embroiled mislocalized Nrf2 in the HGPS-characteristic accelerated
cellular senescence that was consequent of persistent oxidative stress. Progerin, a mutant structural
protein of the nucleus, was found to sequestrate Nrf2 resulting in the latter’s subnuclear
localization and failure to initiate its antioxidative transcriptional program. These events were
reiterated in HGPS progeroid fibroblasts in which Nrf2 was silenced, whereas gain-of-function
experiments abrogated these changes (Kubben et al., 2016).

Several accounts convey the finding that Nrf2 is downregulated in AD brains (Carvalho et al.,
2015; Kanninen et al., 2008; Y. Liu et al., 2016; Manczak et al., 2018). Indeed, Nrf2 ablation
aggravated AD-like pathology in APP/PS1 transgenic (AT) mice (Ren et al., 2020). Of pertinence
to the current report, a study published in Alzheimer's Research & Therapy last year suggests that
Nrf2 activation through the PI3K/Akt/GSK3 axis checks the Aβ-mediated neuronal damage,
ameliorates mitochondrial function and reverses deleterious amyloidopathy-associated metabolic
changes (Sotolongo et al., 2020). Another study published earlier also presented evidence that the
GSK3β/Nrf2 signaling loop is integral to salvaging hippocampal cultures against Aβ detrimental
effects (Zou et al., 2012). A direct connection between Nrf2 and Aβ was elsewhere underscored,
directly implicating Aβ in the dysregulation of the Nrf2/ARE pathway and the dysfunction of the
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antioxidant response to pathogenic amyloid deposition (Simoni et al., 2017). Further evidence
showed that Nrf2 suppresses Beta-secretase 1 (BACE1), the rate-limiting enzyme catalyzing the
formation of Aβ (Bahn et al., 2019). As a matter of fact, quite a few studies reported a modulation
of amyloidopathy via increased Nrf2 transcriptional activity (Dong et al., 2020; S. Kwon et al.,
2015; H. Yu et al., 2019).

Protective Nrf2 upregulation correlated with synucleinopathy in PD patients (Petrillo et al., 2020),
while stereotactic delivery of a Nrf2 activator rescued nigral dopaminergic neurons and relieved
gliosis in mice (Lastres-BeckerIsabel et al., 2016). Additionally, activation of the Nrf2/ARE
signaling blocked neurotoxicity induced by 6-hydroxydopamine (6-OHDA) in SH-SY5Y
neuroblastoma cells (Lou et al., 2014) and rat organotypic nigrostriatal cocultures (Siebert et al.,
2009) and mitigated striatal oxidative stress as well as degeneration of dopaminergic neurons in a
6-OHDA murine model of PD (Lou et al., 2014). Elsewhere, a meta-analysis utilizing microarray
data from PD and AD patients identified 31 ARE transcriptionally repressed genes (Q. Wang et
al., 2017). Moreover, the murine AT-Nrf2 knockout model, which lacks Nrf2 while featuring
coincident tauopathy and amyloidopathy exhibited upregulated markers of neuroinflammation and
oxidative stress when compared to AT-Nrf2 wild type mice (Rojo et al., 2017).

A murine model of ALS bearing the H46R mutant of the Cu/Zn superoxide dismutase (SOD1)
gene retained locomotive functions and displayed a protracted post-onset disease evolvement,
following pharmacologically induced Nrf2 activation (Kanno et al., 2012). NSC‑34 cells harboring
an exogenously introduced G93A mutation of the SOD1 gene displayed shorter and fewer neurites
and rounded soma; these changes were correlated with the dysregulation of Nrf2/ARE signaling
(F. Wang et al., 2014). Furthermore, in vivo overexpression of Nrf2 in astrocytes carrying a SOD1
mutation rescued these cells and resulted in increased production of glutathione, which protected
motor neurons, deferred disease onset and made for better survival rates (Vargas et al., 2008).
What’s more, Nrf2 activation is a well-established modulatory therapy in MS. Dimethyl fumarate
(DMF), marketed under the brand name Tecfidera®, has been a licensed oral therapy for relapsing
remitting MS since 2013 (Brandes & Gray, 2020).

12

Overall, and taking the collective body of literature into account, the multitude of evidence that
support a neuroprotective role for Nrf2 in Alzheimer’s disease (Bahn et al., 2019; Dong et al.,
2020; Kerr et al., 2017; Ren et al., 2020; Uruno et al., 2020), Parkinson’s disease (Alarcón-Aguilar
et al., 2014; Barone et al., 2011; P.-C. Chen et al., 2009; Jazwa et al., 2011; Williamson et al.,
2012), Huntington’s disease (Jimenez-Sanchez et al., 2017; Prasad & Bondy, 2016; Quinti et al.,
2017; van Roon-Mom et al., 2008), multiple sclerosis (Gopal et al., 2017; Owyang et al., 2016),
among others can hardly be refuted.

1.2.1.1. Nrf2 in neuroinflammation

Not only does Nrf2 contribute to shielding against degenerative events of neuronal origin, but it
also mediates a similar homeostatic function to sustain a balanced microglial activation profile,
which – as thoroughly explained above – is essential to the overall neural harmony and imperative
for foreclosing neuroinflammatory events associated with both pro-neurodegenerative and postneurodegeneration

pathologenic

processes.

Attenuation

of

LPS-stimulated

microglial

inflammatory response has been observed following phytochemically induced Nrf2 activation, as
evident by the diminution of the levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α) and
other inflammatory mediators (NO and COX-2) (Townsend & Johnson, 2016; Velagapudi et al.,
2017, 2018; Zheng et al., 2019; Y. Zhou et al., 2019). Nrf2 modulation by a panel of small
molecules produced similar outcomes (Foresti et al., 2013). Additionally, the Nrf2/PI3K/Akt
signaling circuit – noted in neurons and above acknowledged for its relevance to this study – was
replicated in microglia following treatment with sulforaphane, a bona fide Nrf2 activator
(Townsend & Johnson, 2016). Further drawing on the liaison between Nrf2/ARE and the PI3K/Akt
pathways, transactivation of ARE genes by Nrf2 was reported to repress microgliosis via inhibition
of GSK3 in an in vivo model of tauopathy (Lastres-Becker et al., 2014), a condition in which GSK3
is a key player. These results suggest that Nrf2 is mobilized to the nucleus and checks microglial
overactivation induced by aberrant tau forms. In other pathological contexts, microglial dynamics
were determined to be significantly influenced by Nrf2 modulation, where Nrf2 homozygous
knockout mice displayed cognitive impairment coinciding with an augmentation of
proinflammatory cytokines, curtailment of anti-inflammatory mediators and deregulation of
homeostatic signatures viz. TMEM119 and TGFBR1 (Rojo et al., 2010; I.-C. I. Yu et al., 2019).
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Chronic oxidative stress by prolonged cerebral hypoperfusion compromised the integrity of the
BBB in white matter tracts and correlated with higher densities of microglial subsets, which was
evident in Nrf2+/- knockouts yet extensively more significant in the loss-of-function phenotype
(Sigfridsson et al., 2020).
1.3.2. Nuclear factor κ-light-chain enhancer of activated B cells (NF-κB)

Nrf2 is well integrated into a complex regulatory network with modulatory effects on many
signaling cascades, as evidenced by transcription pattern analyses. One particularly relevant
component of the Nrf2 interactome is nuclear factor κ-light-chain enhancer of activated B cells
(NF-κB) (Ahmed et al., 2017). Inflammatory responses are aggravated by ROS and reactive
nitrogen species (RNS) and involve the activation of the canonical subunit of NF-κB, p65 (M. J.
Morgan & Liu, 2010; Wardyn et al., 2015). Interestingly, IKKβ, like Nrf2, also has an ETGE
motif, which – under basal conditions – is recognized by Keap1 and results in the ultimate
ubiquitination of IKKβ and its subsequent degradation by the proteasome (Jiang et al., 2013). An
unphosphorylated IκBα inhibits NF-κB. As is the case with Nrf2, ROS mediate the deactivation
of the regulatory function of Keap1, whereby IKKβ is stabilized and IκBα is phosphorylated and
hence degraded, leading to an upswing of NF-κB (Napetschnig & Wu, 2013). Being the master
coordinator of redox homeostasis, Nrf2 indirectly orchestrates the regulation of NF-κB; the two
transcription factors crosstalk through feedback and feedforward mechanisms. To elaborate, LPS
concomitantly stimulates an acute NF-κB proinflammatory response and a steady, counteracting
Nrf2 response (Cuadrado et al., 2014). NF-κB induces the transcription of Nrf2 thanks to shared
promoter elements (Rushworth et al., 2012). However, when Nrf2 reaches maximal levels, NF-κB
is inhibited (Cuadrado et al., 2014). As such, the anti-inflammatory activity of Nrf2 was suggested
to be partially attributed to its inhibition of NF-κB, as well as its transcriptional inhibition of
proinflammatory genes such as the interleukins IL-1β and IL-6 (E. H. Kobayashi et al., 2016).
According to published reports, NF-κB has been implicated in the regulation of Nrf2-mediated
transcription of ARE genes, although such a role has been reckoned complex and contingent on
the cellular context. A number of mechanisms has been described by which the p65 subunit of NFκB may suppress expression of ARE genes (Wardyn et al., 2015). Overexpression of p65 was
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evinced to repress Nrf2/ARE signaling, where it was demonstrated to hinder the binding of Nrf2
to its cognate DNA sequence. Moreover, p65 was found to physically interact with Keap1 and
mediate its nuclear translocation, which in turn facilitates Keap1-orchestrated post-induction
reversal of Nrf2 activity by exporting it back to the cytosol (Sun et al., 2007; M. Yu et al., 2011).
A more established mechanism by which p65 checks Nrf2 transcriptional activity entails the
competition of both for the transcriptional coactivator, CREB-binding protein–p300 complex
(CBP) (Wardyn et al., 2015). In a groundbreaking work by Liu and colleagues, CBP was shown
to associate with the Neh4 and Neh5 transactivation domains of Nrf2. Once bound to Nrf2, CBP
catalyzes the acetylation of the DNA-binding module that is Neh1, which is overall conducive to
enhanced transcriptional activity. Meanwhile, CBP displays an affinity to p65 bearing a
phosphorylated S276. Thereon, overabundance of p65 seems to favor the expression of NFκB−transcribed genes and limits CBP availability to Nrf2, translating into the transcriptional arrest
of ARE genes (G. H. Liu et al., 2008). The authors also indicated that p65 works to couple Histone
deacetylase 3 (HDAC3) with MafK, which occasions the failure of dimerization with Nrf2 and
abortion of ARE genes transcription. Beyond CBP, other modulators of Nrf2 viz. β-TrCP (Rada
et al., 2011; Winston et al., 1999) and the ubiquitin-binding protein p62 (Ichimura et al., 2013;
Wooten et al., 2005) seem to crosstalk with p65 as well. Perhaps most interesting is the fact that
p65 is also a substrate for GSK3, which is the third player in the mechanistic loop under
investigation. GSK3 is postulated to affect the DNA-binding affinity of p65 (Hoffmeister et al.,
2020; Chandi C. Kandar et al., 2021; Medunjanin et al., 2016; J.-S. Zhang et al., 2014), which
supports the notion that GSK3 activity translates to an inflammatory phenotype, especially when
concomitantly considering its negative regulation of Nrf2. Below, GSK3, the final cog in this
mechanistic machinery is discussed.
1.3.3. Glycogen Synthase Kinase 3 (GSK3)

Many kinases demonstrate an increased activity in neurological disorders; one of these especially
notorious enzymes is GSK3 (Duda et al., 2018). GSK3 is a pleiotropic serine/threonine kinase that
was discovered in the 1980s. It was first identified as a regulator of the enzymatic activity of the
eponymous Glycogen Synthase (Chandi Charan Kandar et al., 2021). Almost 100 proteins have
been recognized as GSK3 substrates and well beyond 500 others are being considered as putative
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targets (Calum Sutherland, 2011), which in effect means that – through phosphorylation of key
residues in its cognate substrates – GSK3 is entrenched in orchestrating normal cellular function
and its dysregulation is invariably linked to pathophysiological events (Eleonore Beurel et al.,
2015).

Of all kinases that have been shown to mediate neuropathogenic protein modifications, GSK3 is
acknowledged as the principal tau-phosphorylating kinase, which led to a growing interest in
GSK3 as a therapeutic target in neurodegenerative tauopathies (Avila et al., 2012; Cuadrado,
Kügler, et al., 2018; G. Lee & Leugers, 2012), beyond its above-described neuroinflammatory
role. GSK3 was found to mediate the phosphorylation of the majority of abnormally
phosphorylated residues in AD (Hanger et al., 2009; Ramkumar et al., 2018). Seeing as tau
primarily functions to stabilize the microtubule network to regulate neuronal dynamics, such
anomalous hyperphosphorylation leads to tau self-assembly (Toral-Rios et al., 2020); this
consequently results in lowered interaction of tau with dynein and kinesin. The ensuing
destabilization of the microtubule network and the cytoskeletal instability within neuronal cells
culminates in the genesis of the characteristic neurofibrillary tangles (Avila et al., 2012; ToralRios et al., 2020).

Back in 2005, a team from the University of Alabama in Birmingham first shed light on the
proinflammatory role GSK3 plays in monocytes, where elevated GSK3 activity correlated with an
upsurge of the proinflammatory cytokines TNF-α, IL-6, and IL-1β (Martin et al., 2005).
Henceforth, GSK3 has been recognized as a pivotal regulator of Toll-like receptor (TLR)
signaling, maintaining the balance between proinflammatory and anti-inflammatory responses,
whether within the CNS or beyond (Ajmone-Cat et al., 2016). GSK3 was also proven to encourage
the microglial inflammatory program, mirroring the effects observed in monocytes. GSK3 incites
microglial activation and provokes overproduction of proinflammatory cytokines, chemokines and
nitric oxide (NO) (Ajmone-Cat et al., 2016; Eléonore Beurel et al., 2009; Cheng et al., 2009;
Yuskaitis et al., 2009). Moreover, GSK3 was found to promote microglial migration, reportedly
via upregulating the complement receptor, the integrin αMβ2 and CD11b, a marker of microglial
activation (Solovjov et al., 2005; Yuskaitis et al., 2009). By the same token, inhibition of GSK3 in
microglia was found to correlate with attenuated NF-κB, signal transducer and activator of
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transcription 3/5 (STAT3/5), p44/p42 mitogen-activated protein kinase (p44/p42 MAPK) and
mixed lineage kinase 3/c-Jun N-terminal kinase 3 (MLK3/JNK) signaling (Eléonore Beurel &
Jope, 2009; Koistinaho et al., 2011; M.-J. Wang et al., 2010). Such modulation of deregulated
signaling is reflected in a marked drop in LPS-stimulated proinflammatory mediators (Il-1β, IL-6,
TNF-α, NO), enhanced production of counteracting anti-inflammatory cytokines (e.g., IL-10),
downregulation of activation markers (e.g., CD11b), and decreased in vitro and in situ microglial
migration, both random and directed, by 50%-70% (Eléonore Beurel et al., 2009; Koistinaho et
al., 2011; Nahman et al., 2011; Nassar & Azab, 2014; M.-J. Wang et al., 2010; Yuskaitis et al.,
2009). It has been conjectured that GSK3 is mixed up in the above-described crosstalk between
activated microglia and injured neurons, exacerbating neuronal loss. Some studies have gone as
far as to conclude that GSK3 overactivity is a primary driver in neuroinflammation-mediated
neuronal loss (D. Li et al., 2014; Yuskaitis et al., 2009), which is on top of the long-established,
inflammation-independent role of GSK3 in neurodegeneration.
GSK3 is one of many kinases that require “priming” before it can carry out its function; that is, it
requires its substrate to have been phosphorylated by another kinase at specific positions, namely
four C-terminal residues away from the phosphorylation site (Frame & Cohen, 2001). Thus, a
general consensus sequence for GSK3-mediated substrate phosphorylation is (S/T-X1-X2-X3pS/pT), where X is any amino acid (Cole et al., 2004). Despite the fact that some unprimed
substrates were reported to be subject of GSK3 regulation, lack of priming is associated with 90%
reduction in GSK3 activity (Calum Sutherland, 2011).
Thanks to evolutionary gene duplication events, multiple paralogs of many genes were generated.
GSK3 is no exception. With a variant on chromosome 19 (GSK3A) and another on chromosome
3 (GSK3B), two protein isoforms (GSK3α and GSK3β) account for GSK3 activity in all mammals
(Woodgett, 1991). Moreover, owing to alternative splicing, GSK3β may exist in two different
mRNA transcripts, GSKβ1 and GSK3β2 (Wood-Kaczmar et al., 2009). The encoded kinase
enzymes have overlapping yet distinct catalytic roles (Soutar et al., 2010). The catalytic domain is
conserved between the two GSK3 isoforms with 98% homology (Calum Sutherland, 2011; Terwel
et al., 2008). The N-terminal region is significantly different, though, with GSK3α boasting a
glycine-rich extension at the N-terminus, resulting in a higher molecular weight of 51 kDa, as
opposed to 47 kDa for GSK3β1 and 49 kDa for GSK3β2 (Calum Sutherland, 2011).
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GSK3 activation is mediated by autophosphorylation of Y279 in GSK3α and Y216 in GSK3β
(Eleonore Beurel et al., 2015), which lends to better substrate accessibility and is purportedly
requisite for optimal assembly of the catalytic site during protein folding (roughly 5-fold
improvement of the catalytic capacity) (Lochhead et al., 2006). A reduced GSK3 activity can
sometimes be subsequent of dephosphorylation of Y279/216. The principal counteractive
influence, however, is played out by inhibitory phosphorylation (Calum Sutherland, 2011). Most
prominently, inhibition occurs by phosphorylation at S21 in GSK3α and S9 in GSK3β, by several
kinases (Cross et al., 1995; Fang et al., 2000; Stambolic & Woodgett, 1994; C Sutherland et al.,
1993). Dephosphorylation of such deactivated GSK3 is carried out by protein phosphatase PP2A,
which catalyzes the removal of the deactivating phosphate groups from the abovementioned serine
residues (Lauretti et al., 2020; Wagner et al., 2018).

The N-terminus of GSK3 features a negative regulatory domain as does its C-terminus; its kinase
domain features the catalytic site as well as the ATP-binding domain (Calum Sutherland, 2011).
Conserved lysine residues (GSK3α: K148 and K149; GSK3β: K85 and K86) within the active site
were determined to mediate ATP binding and catalysis of γ-phosphate transfer to the interfacing
substrate (Hoffmeister et al., 2020). However, within the hinge region of GSK3, the ATP-binding
domain features a single switch of the amino acid glutamate (E196) in GSK3α to the amino acid
aspartate (D133) in GSK3β, resulting in significant topological and structural disparity between
the two paralogs, due to an alteration of hydrogen bonding between the enzyme domains (Wagner
et al., 2018) (Figure 1.3).
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Figure 1.3. Structure of GSK3. (A) Global alignment of murine GSK3α (NP_001026837.1) and GSK3β (NP_001334161.1) proteins by
the Needleman–Wunsch algorithm of NCBI Blast® online tool. Mismatches are highlighted in red. Key motifs and regions are color-coded
as follows: activation loop (blue), hinge region (green), DFG motif (yellow), backend region (purple), and P-loop (orange). (B) 3D
representation of GSK3β protein (PDB ID: 1I09), highlighting the different color-coded regions. In the inset, the hydrogen bonding between
D133 and R113 is highlighted. The images were rendered on the PyMOL Molecular Graphics System, Version 2.5.2 Schrödinger, LLC.
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Unraveling such a subtle difference between GSK3 paralogs, Wagner et al., a team from Broad
Institute at Massachusetts Institute of Technology set out to exploit this single amino acid
substitution and the resulting topological dissimilitude between the isoforms with the purpose of
developing paralog-selective GSK3 inhibitors (Wagner et al., 2018). In context of their work on
acute myeloid leukemia (AML), paralog selectivity was surmised to be a promising approach on
account of the fact that GSK3α inhibition was not associated with stabilization of β-catenin as was
GSK3β inhibition; the pro-malignant transcriptional activity of β-catenin is of concern in AML
patients. The team thereupon developed a set of compounds with remarkable selectivity profiles.
BRD0705, BRD3731 and BRD0320 (pyrazolo-tetrahydroquinolinone ATP competitive GSK3
inhibitors) were presented as GSK3α selective, GSK3β selective and GSK3α/β non-selective
inhibitors, respectively. Below, each of these inhibitors is briefly introduced.
― BRD0705
BRD0705 (CAS No.: 2056261-41-5; Figure 1.4A) is a potent, selective GSK3α inhibitor protected
in the patent US20160375006A1 held by Massachusetts Institute of Technology, Broad Institute
Inc. BRD0705 displays an 8-fold selectivity for GSK3α over GSK3β, and an outstanding
selectivity in a panel of 311 kinases (Scolnick et al., 2016; Wagner et al., 2018). Within a dosing
range of (10-40 μM), BRD0705 hindered the kinase-activating Tyr279 autophosphorylation of
GSK3α in a time-dependent manner, without affecting autophosphorylation of GSK3β at Tyr216
(Wagner et al., 2018). Inability of BRD0705 to stabilize β-catenin was confirmed by a TCF/LEF
luciferase reporter assay, as communicated by Wagner and consociates at the Broad Institute.
― BRD3731
BRD3731 (CAS No.: 2056262-08-7; Figure 1.4B) is a potent, selective inhibitor of GSK3β, also
patented by Massachusetts Institute of Technology, Broad Institute Inc, under the forenamed
patent number. BRD3731 exhibits 14-fold selectivity for GSK3β versus GSK3α, as well as superb
selectivity the same kinome of 311 kinases (Scolnick et al., 2016; Wagner et al., 2018). BRD3731
was shown to stabilize β-catenin in the HL-60 AML cell line, starting at a concentration of 20 uM.
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It restricted the S33/37/T41 phosphorylation of β-catenin and promoted its phosphorylation at
S675, resulting in its improved nuclear accumulation (Scolnick et al., 2016).
― BRD0320

BRD0320 (Figure 1.4C) is a non-selective pan-inhibitor of GSK3. BRD0320 displays 46-fold
selectivity for GSK3 over CDK3/CycE1, the kinase to which BRD0320 exhibits highest affinity
beyond GSK3, as revealed by kinome selectivity assays (Wagner et al., 2018).

Figure 1.4. Chemical structure of BRD0705 (GSK3α inhibitor) (A), BRD3731 (GSK3β inhibitor) (B), and BRD0320 (GSK3α/β
non-selective inhibitor) (C). Structures were drawn using MolView.
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1.4. Rationale

In the current study, we utilize these GSK3 inhibitors to selectively inhibit GSK3 paralogs in the
context of microglial activation. As hereinabove explained, GSK3 is multimodally inculpated in
mediating both neuronal (proteopathic) and glial (inflammatory) etiopathogenic processes in NDs,
especially tauopathies, in which GSK3 dysregulation is a primary pathophysiological feature.
Given the oxidative nature of this disease group in all neural subsets, inhibition of GSK3 can entail
a multimodal modulatory utility by simultaneously targeting the oxidative, inflammatory and
proteopathogenic underpinnings of neurodegenerative disorders; whereby GSK3 inhibition would
stunt pathological phosphorylation events associated with injurious misfolded proteins, alleviate
glia-mediated neuroinflammatory processes, and mitigate oxidative damage in both neurons and
neuroglia. Moreover, given its inability to initiate the pro-malignant β-catenin−driven
transcriptional program, selective inhibition of GSK3α is conjectured to be particularly useful in
individuals with a predisposition to developing neoplasms or actual cancer patients who are at
concomitant risk of age-related proteopathies and/or neuroinflammation by dint of a family history
or, for instance, patients early in the neurodegenerative disease continuum like those scoring
suboptimal scores on mild cognitive impairment (MCI) tests.

1.5. Hypothesis

In light of the numerous reports outlined above, we hypothesized that inhibition of GSK3 in
microglial cells should confer anti-inflammatory and antioxidant effects in microglial cells and
that these effects are likely to be – at least partially – paralog-dependent. Additionally, given the
corroborated crosstalk between GSK3, NF-κB and Nrf2, dysregulation of their interplay was
surmised to occur under proinflammatory conditions, which was conjectured to be favorably
modulated via GSK3 inhibition.
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Figure 1.5. Exploiting the multimodal disease-modifying potential of the GSK3/Nrf2/NF-κB network in inflammatory
degenerative disorders of the CNS. (A) GSK3 mediates several neuropathological events that converge to trigger degenerative
changes in the CNS. It is involved in glial proinflammatory responses and promotes oxidative stress in disparate neural
subpopulations, over and above to its infamous engagement in incentivizing proteopathologies such as tauopathy and
amyloidopathy. (B) GSK3 actuates NF-κB signaling and prompts the proteosomal degradation of Nrf2. In protein pathologies
characteristic of neurodegenerative diseases, GSK3 is notorious for orchestrating the pathological hyperphosphorylation of tau and
encouraging the deposition of amyloid plaques. (C) Under our investigational paradigm, inhibition of GSK3 is rationalized to target
multiple pathological pathways at once. On account of NF-κB suppression resultant of GSK3 inhibition, microglial activation is
surmised to be mitigated. Additionally, blocking GSK3 activity is proposed to have anti-oxidative reverberations in various neural
subsets, on grounds of subsequent Nrf2 activation, which should ultimately dampen the associated parainflammation. Moreover,
the attenuation of GSK3 catalytic activity should preclude hyperphosphorylation of proteins and their subsequent misfolding,
aggregation and deposition. Created with BioRender.com.
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1.6. Objectives and aims

The overarching objective of this study is to compare the anti-inflammatory and antioxidant
potential of paralog-selective inhibition of GSK3 in activated microglial cells. In order to
accomplish this, a number of specific aims, outlined below, were set for experimental investigation
and validation or disproval of related hypotheses.

Specific aims:
1. Comparatively examine the effects of BRD0705 (GSK3α inhibitor), BRD3731 (GSK3β
inhibitor), and BRD0320 (GSK3α/β inhibitor) on modulation of the mRNA expression of
the microglial activation markers CD11b and Iba1 and the proinflammatory mediators IL1β, IL-6, TNF-α, and iNOS in LPS-activated SIM-A9 microglia via real-time qPCR.
2. Establish the ability of BRD0705 (GSK3α inhibitor), BRD3731 (GSK3β inhibitor), and
BRD0320 (GSK3α/β inhibitor) to induce the mRNA expression of the Nrf2 target genes,
HO-1 and Osgin1 in LPS-activated SIM-A9 microglia and discriminately evaluate the
extent to which paralog-selective GSK3 inhibition correlates with Nrf2 activation.
3. Assess the effects of BRD0705 (GSK3α inhibitor), BRD3731 (GSK3β inhibitor), and
BRD0320 (GSK3α/β inhibitor) on LPS-mediated induction of nitric oxide in SIM-A9 cells
using the Griess method and the expression levels of the secretory proteins IL-1β, IL-6,
and TNF-α using ELISA.
4. Determine the effects of BRD0705 (GSK3α inhibitor), BRD3731 (GSK3β inhibitor), and
BRD0320 (GSK3α/β inhibitor) on the nuclear translocation of Nrf2, NF-κB, and β-catenin
by immunoblotting of post-treatment SIM-A9 nuclear lysates.
5. Investigate whether the observed effects of BRD0705 (GSK3α inhibitor), BRD3731
(GSK3β inhibitor), and BRD0320 (GSK3α/β inhibitor) are Nrf2-dependent by employing
small interfering RNA-mediated knockdown of Nrf2, followed by real-time qPCR of the
abovementioned mRNA targets.
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▪ Novelty of this research

The novelty of the proposed work can be realized in its precedence in exploring the differences
between the two GSK3 isoforms. As far as we are aware, this is the first study to compare the
effects of paralog-selective inhibition of GSK3. Adding another dimension to the study is the
exploration of such paralog-selectivity in context of mechanistic characterization of the
oxidative/microglia-mediated neuroinflammatory paradigm of neurodegenerative diseases.
Moreover, this work is the first investigating these regulatory loops in SIM-A9 cells, which – as
will be discussed – the closest cell line to recapitulate characteristics of primary microglial cells.
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2. MATERIALS AND METHODS

2.1. Materials
The SIM-A9 murine microglial cell line (CRL-3265™) was purchased from the American Type
Culture Collection (ATCC). BRD0705 (GSK3α inhibitor), BRD3731 (GSK3β inhibitor) and
BRD0320 (GSK3α/β) were kindly provided by the Broad Institute, Inc (Cambridge, MA, USA) in
accordance with a material transfer agreement. Sulforaphane (SFN; 10496) was purchased from
Cayman Europe OÜ (Tallinn, Estonia). LPS (Escherichia coli O111:B4; L2630) was purchased
from Sigma Chemical Co. (MO, USA). Dulbecco's Modified Eagle Medium/Nutrient Mixture F12 Gibco™ DMEM/F-12, HEPES (31330038), Gibco™ Fetal Bovine Serum (10270106), Gibco™
Horse Serum, heat inactivated (26050070), Gibco™ DPBS, no calcium, no magnesium
(14190094), Dimethyl sulfoxide DMSO (67-68-5), Chloroform (HPLC grade; C607SK-1),
Isopropanol (HPLC grade; BP26324), Ethanol (HPLC grade; 64-17-5), RevertAid cDNA kit
(K1621), PowerUp™ SYBR™ Green (2X) Master Mix (A25741), mRNA (CD11b, IL-6, iNOS,
TNF-α, GAPDH) primers (10629186; designed by NCBI primer blast tool), Pierce™ BCA Protein
Assay Kit (23225) and Pierce™ ECL Western Blotting Substrate (32106) were all acquired from
ThermoFisher Scientific (MA, USA). MTT (M6494), Griess Reagent Kit (G7921), NuPAGE™
LDS Sample Buffer (NP0007), NuPAGE™ Reducing Agent (NP0009), NuPAGE™ 10%, Bis-Tris,
1.0 mm, Mini Protein Gels, 10-well (NP0301), 20X NuPAGE™ MES Running Buffer (NP0002),
NF-κB p65 polyclonal antibody (PA1-186) and Blocker™ BSA (10%) in PBS (37525) were
obtained from Invitrogen (CA, USA). Penicillin-Streptomycin Mixture Pen/Strep (09-757F),
Phosphate Buffered Saline (10X) PBS (17-516Q) were supplied by Lonza-Bioscience (Basel,
Switzerland). QiAzol lysis buffer (79306) and nuclease-free water (129114) were procured from
Qiagen (Hilden, Germany). Protease Inhibitor Cocktail (5871), Phosphatase Inhibitor Cocktail
(5870), Prestained Protein Marker, Broad Range (11-190 kDa) (13953), Nrf2 monoclonal antibody
(12721T), β-Catenin (D10A8) XP® Rabbit mAb (8480) and Secondary goat anti-rabbit HRPconjugated antibody (7074P2) were all requisitioned from Cell Signaling (Danvers, MA, USA).
10X Towbin Buffer (42558.02), 10X TBS Buffer (42596.01), Tween 20 (39796.01) and Methanol
(45631.02) were from SERVA Electrophoresis GmbH (Heidelberg, Germany). Mouse IL-1β
ELISA Kit (E-EL-M0037), Mouse IL-6 ELISA Kit (E-EL-M0044), Mouse TNF-α ELISA Kit (E26

EL-M0049) and Lamin B1 Polyclonal Antibody (E-AB-40257) were obtained from Elabscience
(Houston, TX, USA). HERAPLUS SYBR® Green qPCR Kit (WF10308001) was purchased from
Willowfort (Birmingham, UK) and primers IL-1β, Iba1, c-Myc, HO-1 and Osgin1 (S015950;
designed by NCBI primer blast tool) were ordered from Synbio Technologies (Monmouth
Junction, NJ, USA). TriFECTa RNAi Kit and PrimeTime Assays for Nrf2 (Mm.PT.58.29108649)
and HPRT (Mm.PT.39a.22214828) were supplied by Integrated DNA Technologies (Coralville,
IA, USA), and the Minute™ Cytoplasmic & Nuclear Extraction Kit for Cells (SC-003) was bought
from Invent Biotechnologies (Plymouth, MN, USA).

2.2. Cell culture
According to recommendations by the ATCC, SIM-A9 cells (CRL-3265™) (Figure 2.1) were
maintained in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) medium
supplemented with 10% heat-inactivated fetal bovine serum, 5% heat-inactivated donor horse
serum and 1% Pen-Strep (100 units/mL penicillin, and 100 μg/mL streptomycin) in a 5% CO2
humidified incubator at 37 °C. On reaching a confluence of 80-90% (a cell density averaging about
1.2 × 106 cells/mL), cells were non-enzymatically harvested either by scrapping or a brief (10 min)
incubation with a dissociation solution of 1 mM EDTA, 1 mM EGTA and 1 mg/mL glucose in
calcium/magnesium-free Dulbecco's phosphate-buffered saline. Cells were seeded at densities
ranging from 2×104 cells/mL to 1×106 cells/mL, depending on the experimental procedure. For all
experiments aiming to assess the efficacy of treatments in LPS-activated microglia, SIM-A9 cells
were pretreated with GSK3 inhibitors (or SFN) for 2 h before the cells were treated with E. coli
LPS for 24 h, in continued presence of the treatment compounds. SIM-A9 cell line information as
specified by the ATCC is outlined in Table 2.1.
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Table 2.1: SIM-A9 cell line information
SIM-A9 (CRL-3265™)
Organism

Mus musculus

Strain

C57BL/6

Cell type

Microglial cell

Morphology

Neuronal-like

Tissue

Brain; Cerebral cortex

Biosafety Safety Level

1

Growth properties

Mixed: adherent and suspension

Immortalization method

Spontaneous immortalization

Antigen expression

CD68+; ionizing calcium-binding adaptor molecule 1 (Iba1)+
Base medium: DMEM/F12
Complete medium: DMEM/F12 supplemented with heat-

Growth Medium

inactivated horse serum to a final concentration of 5% and
heat-inactivated fetal bovine serum to a final concentration of
10%.

Culture Conditions

37 °C, 5% CO2 in air atmosphere

Subcultivation Ratio

1:3 to 1:6

Medium renewal

every 2 to 3 days

Reagents for cryopreservation

Complete growth medium supplemented with 10% (v/v)
DMSO
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A

B

C

D

Figure 2.1. SIM-A9 cells ATCC® CRL-3265. Reference 10X micrographs of the SIM-A9 cell line at a low density (A) and a high
density (B). Micrographs captured at 20X magnification on reaching confluency (C) and (D).
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2.3. Cell Viability: MTT Assay
SIM-A9 cells were seeded in 96-well microtiter plates at a density of 1×105 cells/mL and allowed
to acclimate overnight. To determine non-cytotoxic concentrations of the experimental
compounds, the cells were then treated with different concentrations (10 μM, 20 μM, 40 μM and
80 μM) of GSK3 inhibitors for 24 h. Sulforaphane (SFN), used as a positive control for countering
inflammation and Nrf2 activation, was also evaluated for its cytotoxicity at different molarities (1
μM, 5 μM, 10 μM). Additionally, varying concentrations (10 ng/mL, 100 ng/mL and 1 μg/mL) of
E. coli LPS (O111:B4) were similarly evaluated.

Based on the results from these preliminary experiments and informed by the results of the Griess
assay, concomitant treatment with LPS at a concentration of 100 ng/mL and GSK3 inhibitors at
the concentrations 10 μM, 20 μM, and 40 μM, or SFN at 5 μM were also evaluated for their
cytotoxic effects to simulate subsequent experimental conditions. For these experiments, the cells
were seeded at a density of 5×105 cells/mL, given that this cellular concentration produced the
optimal response to stimulation by LPS in the Griess experiment. All treatments were prepared in
serum-free DMEM/F12 medium.

Cell viability following treatments was determined using the MTT colorimetric assay. The cellular
metabolic activity was used as an indicator for cell viability, where only viable and metabolically
active cells are capable of reducing the MTT tetrazolium dye to chromogenic formazan crystals.
Following a 24 h incubation of the treatments with the cells, the culture medium was aspirated off
and replaced with 100 μL of (1 mg/mL) MTT solution prepared in serum-free DMEM/F12
medium. Subsequent to a further 2 h incubation, the MTT solution was discarded, and the insoluble
formazan crystals formed were dissolved in 100 uL DMSO. Absorbance was measured at 540 nm
using NanoSPECTROstar microplate reader (BMG LABTECH, Ortenberg, Germany) and cell
viability was calculated relative to untreated controls.
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2.4. Determination of Nitrite: Griess Method

To preliminarily evaluate the anti-inflammatory capacity of the experimental compounds, the
concentration of nitrite in the culture medium was determined using the Griess method. Nitrite
concentration serves as an indicator for the levels of NO produced in the course of the LPS-initiated
inflammatory response. The Griess reaction was performed following a treatment protocol in
which cells were pretreated with the GSK3 inhibitors (10 μM, 20 μM, and 40 μM) or SFN (5 μM)
for 2 h and then stimulated with 100 ng/mL LPS for 24 h, with continued exposure to the
compounds. Thereafter, 150 μL of cell culture media were diluted with 130 μL of deionized water
and 20 μL of the Griess reagent (1:1 mixture of 1% sulfanilamide in 5% phosphoric acid and 0.1%
naphthylethylenediamine dihydrochloride in water) were added to the diluted supernatant.
Following a 30 min incubation in the dark to permit the diazotization reaction, the color of the
formed azo chromophore was spectrophotometrically measured at 548 nm using Nano
SPECTROstar microplate reader, where the optical density of the nitrite-azo dye commensurately
corresponds to the concentration of nitrite in the sample. The concentration of nitrite in each
sample was computed using the linear equation generated from a standard curve, which was plotted
using the recorded absorbance values for various concentrations of a nitrite standard.
2.5. Treatment and isolation of total RNA
SIM-A9 cells were seeded in 6-well plates at a density of 1×106 cells/mL and allowed to acclimate
overnight. The cells were then treated with GSK3 inhibitors at the concentrations 10 μM and 20
μM, or SFN at 5 μM for 2 h. Afterwards, the media were aspirated off and the cells treated with a
mixture preserving the same abovementioned concentrations of the compounds with the addition
of LPS at a concentration of 100 ng/mL to induce microglial activation in the presence of the
GSK3 inhibitors or SFN. Following a 6 h incubation, total RNA was extracted by lysing the cells
using the phenol/guanidine-based QIAzol Lysis Reagent as per the manufacturer’s instructions.
To lyse the cells, 1 mL of the QIAzol reagent was added to each well and – following a brief
trituration – the cell lysates were incubated at room temperature for 5 min before collection into
separate microcentrifuge tubes. To each tube, 200 μL chloroform were added and vigorously
shaken with the lysate for 15 sec. The homogenate was allowed to rest for 2-3 min at room
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temperature and then centrifuged at 12,000 ×g for 15 min at 4 ℃ for phase separation. The upper
aqueous phase from each sample, where the RNA partitions, was transferred into a new tube and
the DNA/protein-containing organic layer was discarded. To salt the RNA out of the aqueous
isolate, 500 μL isopropanol were added to each tube. The solution was then thoroughly vortexed
for optimal mixing and maximal RNA recovery and thereafter centrifuged at 12,000 ×g for 10 min
at 4 ℃, following a 10 min benchtop incubation. The supernatant was carefully aspirated off and
the pelleted RNA was briefly vortexed in a 75% ethanol wash before a final centrifugation at 7,500
×g for 5 min at 4 ℃. Finally, the supernatant was discarded, and the RNA pellet was allowed to
air-dry before being resuspended in 25 μL nuclease-free water. The RNA isolates were quantified
and checked for purity by recording their optical densities at 260 nm (ng/μL) and the A260/A280
ratio (indication of absence or presence of protein and DNA contaminants) using the NanoDrop™
One/OneC Microvolume UV-Vis spectrophotometer. The RNA samples were stored at -80 ℃ for
downstream experiments.
2.6. cDNA Synthesis

First strand cDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit in line
with the manufacturer’s instructions. In brief, 1 μg of RNA* from each sample was watered down
to 10 μL with nuclease-free water. Next, 10 μL of the cDNA mastermix (Table 2.2) were added to
each RNA sample for a total reaction volume of 20 μL. The cDNA reactions were amplified in a
96-well Thermal Cycler (Applied Biosystems™, CA, USA) according to the following cycling
conditions: 25 ℃ for 5 min (necessary for extension by random hexamer primers), followed by 42
℃ for 60 min (for extension primed by both random hexamers and oligo(dT)18 primers), and then
70 ℃ for 5 min to terminate the reaction. Finally, the reactions were cooled down to 4 ℃ and then
stored at -20 ℃ until further use. Prior to gene quantitation by qPCR, the cDNA reactions were
diluted by nuclease-free water in a 1:3 ratio (40 μL nuclease-free water added to the final cDNA

*

For synthesizing cDNA from post-knockdown RNA templates, 500 ng RNA were used to synthesize cDNA, instead
of 1 μg (given lower RNA concentrations). cDNA reactions were diluted in a 1:5 ratio (80 μL nuclease-free water
added to the final cDNA reaction volume of 20 μL) to produce enough template for the intended qPCR runs and avoid
inconsistency issues secondary to using cDNA from different knockdown experiments. For qPCR, 2 μL of cDNA
were used, amounting to 10 ng cDNA/reaction.
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reaction volume of 20 μL). For qPCR, 3 μL of cDNA were used as a template, amounting to 50
ng cDNA/reaction.

Table 2.2. RevertAid cDNA Reaction Composition
Reaction Component

Volume per reaction (μL)

5X Reaction Buffer

4

Oligo (dT)18 primer

1

Random Hexamer Primer

1

RiboLock RNase Inhibitor (20 U/µL)

1

10 mM dNTP Mix

2

RevertAid M-MuLV RT (200 U/µL)

1

Total volume

10

2.7. Quantification of mRNA using real-time PCR (qPCR)

The mRNA expression levels of microglial activation markers (CD11b and Iba1), inflammationrelated genes (iNOS, IL-1β, IL-6, TNF-α), Nrf2 target genes (HO-1 and Osgin1) and the β-catenindriven c-Myc were quantified by real-time quantitative polymerase chain reaction using the ABI
Prism 7500 real-time PCR system (Applied Biosystems, CA, USA). Expression was normalized
to GAPDH, and relative fold gene expression was computed using the comparative CT (ΔΔCT)
method. Specific primer pairs were generated via the NCBI Primer-Blast tool and purchased from
ThermoFisher or Synbio Technologies; primer sequences are shown in Table 2.4. For primer
reconstitution, the lyophilized primers were briefly centrifuged and hydrated in 10 times their
molecular weight (expressed in nanomoles) in nuclease-free water to yield a 100 µM primer stock
solution, from which 10 µM working stocks were prepared. A melting curve was generated at the
end of each qPCR run to exclude any instances of primer dimer formation and confirm primer
specificity (amplicon purity). The qPCR master mix comprised 6.25 µL of PowerUp™ SYBR™



(https://www.ncbi.nlm.nih.gov/tools/primer-blast/)
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Green (2X) Master Mix or HERAPLUS SYBR® Green qPCR master mix, 0.375 µL of 10 µM
forward primer and 0.375 µL of 10 µM reverse primer (equivalent to a final primer concentration
of 300 nM) in addition to 2.5 µL of nuclease-free water to make up a final volume of 9 µL added
to 3 µL cDNA (50 ng of template/reaction) (Table 2.3). The reactions were prepared in
MicroAmp™ Optical 8-Tube Strip, 0.2 mL (Applied Biosystems™; CAT# 4316567), carefully
capped using MicroAmp™ Optical 8-Cap Strips (Applied Biosystems™; CAT# 4323032) and
subjected to the following thermocycling conditions: an initial holding stage run at 95 ℃ for 10
min, followed by 40 2-step cycles of denaturation at 95 ℃ for 15 sec then annealing/extension for
60 sec at 60 ℃; data collection was set to occur during step 2.
Table 2.3. SYBR green mRNA qPCR reaction
Volume per reaction (μL)

Component
PowerUp™ SYBR™ Green (2X) Master Mix

6.25

Forward Primer (0.3 µM)

0.375

Reverse Primer (0.3 µM)

0.375

Nuclease-free water

2.5

cDNA

3
Total volume

12.5

For post-knockdown qPCR experiments, variations to the above protocol are hereunder
summarized. PrimeTime™ qPCR primers for Nrf2 and HPRT were purchased from Integrated
DNA Technologies (Coralville, IA, United States) as predesigned primer assays. As per the
manufacturer’s guidelines, the primer tubes were centrifuged, and the primers resuspended in 500
µL nuclease-free water to make a 20X stock solution. The composition of the qPCR master mix
was modified as follows: 5 µL of HERAPLUS SYBR® Green qPCR master mix, 0.5 µL of 20X
PrimeTime qPCR primer assay (equivalent to a final primer concentration of 500 nM) in addition
to 2 µL of nuclease-free water to make up a final volume of 8 µL added to 2 µL cDNA (10 ng of
template/reaction).
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Table 2.4. List of primers used for qPCR
Target mRNA
CD11b
Iba1
IL-6
IL-1β
iNOS
TNF-α
Nfe2l2
HO-1
Osgin1
c-Myc
GAPDH
HPRT

Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:
Forward Primer:
Reverse Primer:

Sequence (5’-3’)
AAGCAGCTGAATGGAGGAC
GGGCCCCATTGGTTTTGTGAA
CCTGCAGACTTCATCCTCTC
AGGCATCACTTCCACATCAG
GATGCTACCAAACTGGATATAATCAG
CTCTGAAGGACTCTGGCTTTG
AAAGCTCTCCACCTCAATGG
TTGGGATCCACACTCTCCAG
GGAACCTACCAGCTCACTCTGG
TGCTGAAACATTTCCTGTGCTGT
GAACTCCAGGCGGTGCCTAT
TGAGAGGGAGGCCATTTGGG
TGATGGACTTGGAGTTGCC
TCAAACACTTCTCGACTTACTCC
CACAGATGGCGTCACTTCGTC
GTGAGGACCCACTGGAGGAG
CGGTGACATCGCCCACTAC
GCTCGGACTTAGCCCACTC
AGCTGTTTGAAGGCTGGATT
CTGCTGTTGCTGGTGATAGA
CTTTGTCAAGCTCATTTCCTGG
TCTTGCTCAGTGTCCTTGC
CCCCAAAATGGTTAAGGTTGC
AACAAAGTCTGGCCTGTATCC

Tm (℃)
55
55
57
55
55
58
55
57
63
60
63
63
55
54
60
62
62
62
53
55
57
58
55
55

For analysis of the generated real-time PCR amplification output and as per the User Bulletin 2 of
Applied Biosystems (User Bulletin #2 ABI PRISM 7700 Sequence Detection System), the secondderivative algorithm “2-ΔΔCT” was employed to determine gene expression relative to a
housekeeping reporter gene in treated samples versus untreated controls (comparative CT or ΔΔCT
method). For every gene of interest, ΔCT values were determined for each sample as the difference
between the CT values obtained for the target gene and the reporter gene in the same sample (CT
gene of interest

– CT housekeeping gene), where GAPDH (or HPRT in post-knockdown qPCR assessment of

proinflammatory markers) was used as the housekeeping reporter gene. Relative changes in
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expression of any given gene (ΔΔCT) were then calculated as the difference between the ΔCT of
each treatment group and the average ΔCT of the untreated control group. Finally, fold change of
expression was determined as 2-ΔΔCT, individually calculated for each group. The values are
expressed in the figures as (2-ΔΔCT ± SE), where SE is the standard error of the mean of the 2-ΔΔCT
values.
2.8. Quantification of secretory proinflammatory cytokines using ELISA
Pre-coated micro-ELISA plates from Elabscience® were used to quantify the protein expression of
the proinflammatory cytokines IL-1β, IL-6 and TNF-α in the supernatant of SIM-A9 cells
stimulated with LPS in the presence of GSK3 inhibitors or SFN, following the treatment protocol
above. In short, the cells were seeded in 6-well plates at a density of 1×106 cells/mL. Following
overnight incubation, the cells were pretreated with GSK3 inhibitors at the 20 μM concentration
or SFN at 5 μM for 2 h. The media were then removed and replaced with fresh media containing
100 ng/mL of LPS, while maintaining the concentration of GSK3 inhibitors at 20 μM and SFN at
5 μM. The culture media were collected 24 h later, centrifuged at 1,000 ×g for 20 min at 4 ℃ and
the supernatant transferred to clean microcentrifuge tubes.

2.8.1. Sample preparation
For IL-6 and TNF-α, the supernatant was diluted in a ratio of 1:20 in the kit-provided Reference
Standard and Sample Diluent, whereas undiluted samples were used for detection of IL-1β.

2.8.2. Reagent preparation

2.8.2.1. Wash buffer
As per the manufacturer’s recommendations, 30 mL of concentrated (25X) wash buffer were
diluted in 720 mL of deionized water to give 750 mL of a 1X working solution, for each plate.

2.8.2.2. Standard working solution
Vials containing the reference standard were centrifuged at 10,000 ×g for 1 min and then
reconstituted in 1 mL of the Reference Standard and Sample Diluent to give 2000 pg/mL (IL-6
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and TNF-α) and 500 pg/mL (IL-1β) working solutions. Serial dilutions were prepared following
the recommended dilution gradient for each standard.

2.8.2.3. Biotinylated detection antibody working solution
A vial containing 120 μL of (100X) biotinylated detection antibody was centrifuged at 800 ×g for
1 min and then diluted in 11.88 mL of the included Biotinylated Detection Antibody Diluent to
make 12 mL of a 1X working solution, for each plate.

2.8.2.4. HRP conjugate working solution
A 1X working solution was prepared from a 100X concentrated stock exactly as outlined for the
biotinylated detection antibody working solution.

2.8.3. Assay
Following the sandwich ELISA principle, 100 μL of each sample or standard dilution were
pipetted into their assigned wells to bind the well-coating antibody that captures its cognate antigen
in the added sample or standard. Samples were assayed in triplicates and each standard
concentration in duplicates. The plate was then covered with a plate sealer and incubated at 37 ℃
for 90 min. Afterwards, the plate was decanted and 100 μL of the (1X) biotinylated detection
antibody working solution (also specific to the antigen of interest) were added immediately,
without washing. The plate was covered with a new sealer and again incubated at 37 ℃ for 1 h.
By the end of this incubation, the antigen of interest should be sandwiched between the wellcoating antibody and the biotinylated antibody. Subsequently, the antibody solution was removed
and 350 uL of wash buffer were added to each well and the plate allowed to soak for 1 min before
the wash solution was removed. Following two more washes, 100 μL of the 1X HRP working
solution were added to each well and the cover-sealed plates incubated at 37 ℃ for 30 min; this
Avidin-HRP conjugate binds the biotin-tagged antibody that is now bound to the protein of
interest. The plate was thereafter decanted and washed five times as outlined hereabove, before 90
μL of 3,3'5,5'-Tetramethylbenzidine (TMB) HRP-substrate were added to each well. For one last
time, the sealed plate was incubated at 37 ℃ for 20 min. Only wells containing the antigen should
have formed the antigen-antibody-HRP complex and bound the substrate, producing a blue color.
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To terminate the enzymatic reaction, 50 μL of stop solution were added to each well in the same
order the substrate was added; the developed blue color immediately shifts to yellow on adding
the acidic stop solution. Optical density was measured at 450 nm using NanoSPECTROstar
microplate reader (BMG LABTECH, Ortenberg, Germany). A standard curve was obtained by
plotting the recorded OD values from reference standard wells against their respective
concentrations. The linear equation generated from the standard curve was used to compute the
protein concentration within each sample. The concentrations calculated for diluted samples were
multiplied by the dilution factor to give the actual concentration of the original protein prep.

2.9. Fractionation of total cell lysates into nuclear and cytoplasmic extracts

In order to evaluate the effect of inhibition of GSK3 paralogs on the transcriptional activity of Nrf2
and NF-κB p65, nuclear lysates of treated SIM-A9 cells were extracted using the Minute™
Cytoplasmic and Nuclear Extraction Kit for Cells to assess the translocation of these transcription
factors to the nucleus following treatment. SIM-A9 cells seeded at a density of 1×106 cells/mL in
6-well plates were pretreated with GSK3 inhibitors at the concentration 20 μM or SFN at 5 μM for
2 h. Following an additional 24 h incubation with 100 ng/mL LPS in the presence of the test
compounds, the cells were washed in ice-cold PBS buffer and then 300 μL cytoplasmic extraction
buffer, containing 1X Protease Inhibitor Cocktail and 1X Phosphatase Inhibitor Cocktail, were
added to each well. The plates were placed on ice for 5 min before the lysed cells were scraped off
and the cell lysates were transferred to pre-chilled microcentrifuge tubes and vortexed vigorously
for 15 sec. The tubes were then centrifuged at 12,000 ×g for 5 min at 4 ℃. The supernatant
(cytosolic fraction) was transferred to a clean tube and stored at -80 ℃ for future use. As per the
manufacturer-recommended buffer volume to culture container ratio, 150 μL nuclear extraction
buffer, also containing 1X Protease Inhibitor Cocktail and 1X Phosphatase Inhibitor Cocktail, were
added to the pelleted nuclei and the mixture forcefully vortexed for 15 sec then incubated on ice
for 1 min. The last step was repeated 4 times alternating between vigorous vortexing for 15 sec
and 1 min incubation on ice. The nuclear extracts were then transferred to pre-chilled filter
cartridges mounted onto collection tubes and centrifuged at 16,000 ×g for 30 sec. The filter
cartridges were then discarded, and the collected nuclear extracts were stored at -80 ℃ until future
use.
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2.10. Quantification of cytoplasmic and nuclear proteins
The concentrations of total cytoplasmic and nuclear proteins were determined using the Pierce™
BCA Protein Assay Kit, which employs a colorimetric method for protein quantification based on
the two-step biuret reaction. The first step of the reaction involves the reduction of Cu+2 from
Copper(II) sulfate to Cu+1 by proteins in the sample. The amount of Cu+2 ions reduced is thus
proportional to the amount of protein in the sample. Two molecules of bicinchoninic acid (BCA)
then chelate the newly formed Cu+1 ions giving a purple water-soluble complex that can be
optically measured.

2.10.1. Reagent Preparation

2.10.1.1. Preparation of diluted albumin (BSA) standards

An ampule of 2 mg/mL bovine serum albumin standard (BSA) was used to prepare eight standard
concentrations within the range of 25-2000 μg/mL, according to the dilution scheme recommended
by the manufacturer. Standard dilutions were prepared using the same lysis buffer in which the
samples were prepared, and each dilution was assayed in triplicates.

2.10.1.2. Preparation of the BCA working reagent
The BCA working reagent was prepared by mixing 50 parts of BCA Reagent A to 1 part of BCA
Reagent B, giving a clear, green-colored working reagent.

2.10.2. Assay
In a 96-well microtiter plate, 25 μL of each sample and standard dilution were added to the
designated wells. For blanking, 25 μL of lysis buffer were added to the respective wells. Every
sample or standard dilution was assayed in triplicates. In each well, 200 μL working BCA reagent
were added, the plate was thoroughly mixed on an orbital shaker for 30 sec and then incubated at
37 ℃ for 30 min. The plate was then cooled down and the absorbance of the formed colored
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complexes measured at 562 nm using NanoSPECTROstar microplate reader (BMG LABTECH,
Ortenberg, Germany). Sample concentrations were computed from the line equation generated by
plotting OD values for varying concentrations of a bovine serum albumin standard.

2.11. Western Blotting
Western blotting for nuclear Nrf2, NF-κB p65, and β-catenin was carried out in denaturing and
reducing conditions. Samples were prepared such that the loading volume of 25 μL would contain
15 μg of protein per well. Each sample was prepared in 1X NuPAGE™ LDS Sample Buffer and
1X NuPAGE™ Reducing Agent and completed to volume with deionized water. The samples
were briefly vortexed, spun down and heated at 70 ℃ for 10 min. The samples were then run on
NuPAGE™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gels (10-wells) in an XCell SureLock™ MiniCell containing 600 mL running buffer in its lower chamber and 200 mL in its upper chamber. To
prepare 1X SDS running buffer, 50 mL of 20X NuPAGE™ MES Running Buffer were added to
950 mL deionized water. In each well, 25 μL sample (containing 15 ug protein) were loaded; 5 μL
of a pre-stained protein marker, were introduced into wells assigned for molecular weight
reference. Gels were run at 200 V for 35 min, using the PowerEase® 90W Power Supply
(Invitrogen™, CAT# PS0091). For blotting the gels, 1X transfer buffer was prepared by adding
50 mL of 10X Towbin buffer and 100 mL methanol to 850 mL deionized water to yield 1X transfer
buffer containing 10% methanol, for blotting one gel. In case two gels were blotted simultaneously,
the transfer buffer was prepared so as to contain 20% methanol. Blotting pads and filter papers
were presoaked in around 700 mL of the prepared transfer buffer. Polyvinylidene fluoride (PVDF)
membranes were activated in methanol for 30 sec and then washed in deionized water before
soaking in transfer buffer. The blotting sandwich was prepared in an XCell II™ Blot Module
(Invitrogen™, CAT# EI9051) The blotting module was then clamped, inserted into the XCell
SureLock™ Mini-Cell and filled with 200 mL transfer buffer; the outer chamber was filled with
650 mL deionized water to prevent overheating. Blotting was set to run for 1 hour at 30 V.
Following completion of transfer, membranes were briefly washed in 1X TBST buffer and blocked
using 5% BSA in 1X TBST for 1 h on an orbital shaker. Subsequently, the membranes were
washed 3 times in 1X TBST for 5 min, after which, primary anti-mouse Nrf2 monoclonal antibody
(1:1,000), anti-mouse β-catenin monoclonal antibody (1:1000), anti-mouse NF-κB p65 polyclonal
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antibody (1:2,000) or anti-mouse Lamin B1 polyclonal antibody (1:1,000) were added to the
membranes and incubated at 4 ℃ overnight, on a shaker. Next, the primary antibodies were
removed, and the membranes washed 3 times in 1X TBST. Secondary goat anti-rabbit HRPconjugated antibody (1:2,500) was then added to the membranes and incubated on a shaker for an
hour at room temperature. After removal of the secondary antibody and five repeated 5 min washes
with 1X TBST, Pierce™ ECL Western Blotting Substrate was added to the membranes in a 1:1
ratio of peroxide solution to luminol enhancer. Chemiluminescence was measured using the
ChemiDoc™ Imaging System (Bio-Rad®, CAT# 12003153); densitometric analysis of the bands
was carried out using the Image Lab 6.1 software, using Lamin B1 as a loading control.

2.12. Transfection of SIM-A9 cells with Nrf2-targeting siRNAs

For transfection of SIM-A9 cells, the TriFECTa RNAi Kit from Integrated DNA Technologies
was used; this kit utilizes 27mer duplex RNAs optimized for processing by Dicer (DsiRNAs),
instead of the conventional 21mer siRNAs. The kit contains 3 different predesigned Nrf2-targeting
DsiRNAs (Table 2.5) in addition to a non-targeting negative control DsiRNA, an HPRT-targeting
positive control DsiRNA and a TYE 563 Transfection Control DsiRNA. Lipofectamine™ 3000
was used as the transfection reagent.

Tubes containing the dried annealed oligos were briefly spun down in a microcentrifuge and then
the duplexed oligos were resuspended in nuclease-free buffer to make 100 μM stock solution from
which 20 μM working stocks were prepared. To prepare a 20 μM working stock of Nrf2-targeting
DsiRNA pool from the 3 DsiRNAs, equal volumes from the 100 μM stock of each DsiRNA were
mixed to yield a DsiRNA cocktail of a concentration one-third the original of each individual
DsiRNA. A 20 μM working stock of this DsiRNA pool was then prepared and used to make a 10
nM treatment solution of pooled Nrf2-targeting DsiRNAs in DMEM/F12 basal medium.
Lipofectamine™ 3000 was similarly diluted in basal DMEM/F12 such that 3.75 μL are added to
each well of a 6-well plate.
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Table 2.5. Nrf2-targeting DsiRNAs
DsiRNA (IDT
Duplex Name)

Strand

5’-3’
Nrf2 dsiRNA 1
(mm.Ri.Nfe2l2.13.1)

Nrf2 dsiRNA 2
(mm.Ri.Nfe2l2.13.2)

Nrf2 dsiRNA 3
(mm.Ri.Nfe2l2.13.3)

Duplex Sequences

IDT Ref.
No.

Targeted
Transcript (NCBI
Reference
Sequence; bp
range)

228168776

Nrf2 transcript
variant 1
(NM_010902.4; bp
range: 2201-2227)

228168779

Nrf2 transcript
variant 1
(NM_010902.4; bp
range: 1071-1097)

228168782

Nrf2 transcript
variant 1
(NM_010902.4; bp
range: 1728-1754)

AAAGUCUCAAUGUUGAAUCAGUUTC

3’-5’

AAUUUCAGAGUUACAACUUAGUCAAAG

5’-3’

GCGAUGAAUUUUAUUCUGCUUUCAT

3’-5’

ACCGCUACUUAAAAUAAGACGAAAGUA

5’-3’

AUAUACGCAGGAGAGGUAAGAAUAA

3’-5’

UCUAUAUGCGUCCUCUCCAUUCUUAUU

Given the notoriety of macrophages for being difficult-to-transfect cells and driven by the fact that
reverse transfection is often more conducive to a higher transfection efficiency, SIM-A9 cells were
reverse-transfected. For complexing, Lipofectamine™ 3000 and DsiRNAs, both diluted in basal
DMEM/F12 medium, were added to each other in a 1:1 ratio, such that the manufacturerrecommended volume of transfection reagent/well is maintained at 3.75 μL and the formed lipid
complex encapsulates 10 nM DsiRNA. The mixture was incubated for 20 min for complete
complexing. Afterwards, 750 μL cell suspension (equivalent to 6 × 105 cells/well) and 250 μL of
the DsiRNA-lipid complex were added to each well. The plates were thoroughly mixed and
incubated in a 5% CO2 humidified incubator at 37 °C for 24 h. Fluorescence in cells transfected
with the TYE 563-labeled Transfection Control DsiRNA (Absorbance Maximum: 549 nm –
Emission Maximum: 563 nm) was checked under the Olympus IX70 Inverted Fluorescent Light
Microscope at 6 h and 24 h. The next day, the media containing the transfection complex was
discarded and the treatment protocol commenced as hereabove outlined. Following a 6 h
incubation with LPS and GSK3 inhibitors (20 uM) or SFN (5 uM), the cells were lysed in QIAzol
Lysis Reagent. Total RNA was thereafter extracted and processed for qPCR experiments as
previously described.
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2.13. Statistical Analysis

One way Analysis of variance (ANOVA) followed by Student–Newman–Keuls post hoc test was
applied to determine the statistical significance among the various study groups. A threshold value
of 0.5 was set for the probability value (P-value), with P < 0.05 considered statistically significant.
The data are presented as the means ± standard error of the mean (SE) for the designated number
of independently executed experiments. Comparative analysis among study groups was carried
out via SigmaPlot (Version 14.0; Systat Software, Chicago, IL, USA) and GraphPad Prism
(Version 9.0.0; San Diego, CA, USA). Data was graphically rendered in GraphPad Prism.
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3. RESULTS
3.1. Interaction enrichment of the Nrf2/NF-kB/GSK3/β-catenin network

To preliminarily validate the robustness of the inferred functional association network involving
the key protein players (Nrf2, NF-κB, GSK3, and β-catenin) under study, the STRING database
was interrogated for interactions between these molecular targets. The analysis returned 4 nodes,
1 for each protein and 6 edges, representing the interactions between them (Figure 3.1). The
network was determined to have significantly more interactions than expected, with a proteinprotein interaction enrichment P-value totaling 0.0097. As indicated by the STRING database, this
interaction enrichment means that our proteins have more interactions among themselves than
what would be expected for any random set of proteins of the same size and degree distribution
drawn from the genome; it entails that these proteins are at least partially biologically connected
as a group. Full functional enrichments for this association network can be found at the following
permalink:
https://version-11-5.string-db.org/cgi/network?networkId=bJ9KyjAgorhs.

This enrichment analysis was withdrawn from 9920 publications, 33 KEGG pathways, and 16
Wikipathways, assuming the whole Mus musculus genome (NCBI taxonomy ID: 10090) for
statistical background.
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Figure 3.1. A simplified representation of the interaction enrichment of the Nrf2/NF-kB/GSK3/β-catenin association
network. This network can be expanded for higher complexity associations from the permalink hereabove provided. Each node
represents a protein within the network. Splice isoforms and post-translational modifications are collapsed; each node represents
all forms of a protein encoded by a single protein-coding gene locus (details can be viewed at the above permalink). The internodal
edges represent protein-protein interactions; an edge represents a functional interaction and does not necessarily mean a physical
association between any two proteins. Cyan-colored edges represent known interactions from curated databases, violet-colored
edges represent experimentally determined interactions, black edges indicate co-expression tendencies and lime-colored edges
represent interactions derived from text mining.
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3.2. Effect of LPS on viability of SIM-A9 cells

For the purposes of this study, LPS is used to stimulate a proinflammatory program in SIM-A9
microglia. The MTT assay and the Griess method were conjointly employed to determine the
optimal concentration of LPS at which maximal microglial activation can be achieved, without
compromising cell viability (Figure 3.2 and Figure 3.4). To that end, SIM-A9 seeded at varying
densities were treated with LPS at the following concentrations: 10 ng/mL, 100 ng/mL and 1
μg/mL. Subsequent of measuring nitrite levels in the culture media from each group to determine
the LPS concentration/cell density combination of the strongest proinflammatory response, the
metabolic activity of the cells was assayed using the MTT reagent as outlined above. Lower
seeding densities were associated with increased cytotoxicity at the 100 ng/mL and the 1 μg/mL
concentrations; where viability of cells seeded at a density of 0.5×105 cells/mL (1×104 cells/well
of a 96-well microplate) was reduced by 33.89% at the 100 ng/mL concentration and by 44.61%
at the 1 μg/mL concentration. Cells seeded at a density of 1×105 cells/mL (2×104 cells/well of a
96-well microplate) fared considerably better with only a 5.72% reduction of cell viability at the
100 ng/mL concentration and a further decline by 18.3% at the 1 μg/mL concentration. On the
other hand, seeding densities of 2.5×105 cells/mL (5×104 cells/well of a 96-well microplate) and
5×105 cells/mL (10×104 cells/well of a 96-well microplate) only exhibited a significant drop of
viability at the 1 μg/mL LPS concentration, with 46.75% and 37.46% decline in viability,
respectively. However, cells seeded at both these densities maintained acceptable rates of viability
for downstream experimentation when treated with 100 ng/mL LPS, with only 7.27% and 6.51%
decrease in viability at the 2.5×105 cells/mL and 5×105 cells/mL cellular concentrations,
respectively. LPS administered at 10 ng/mL was not associated with significant cytotoxicity across
all cell densities. Given that treatment of cells seeded at 5×105 cells/mL with LPS at the 100 ng/mL
concentration was associated with the highest nitrite levels (as will be shown), while maintaining
a good viability profile (Figure 3.2), these conditions were adopted for subsequent experiments.
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Figure 3.2. Effect of LPS on viability of SIM-A9 cells. Cell viability/LPS cytotoxicity was assessed using the MTT assay
following treatment of SIM-A9 cells (5 × 105 cells/mL) with 10 ng/mL, 100 ng/mL and 1 μg/mL LPS. Data is expressed as means
± SEM. Group comparisons were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; $ P-value
< 0.05 (relative to negative [untreated] controls).
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3.3. Effect of BRD0705, BRD3731, BRD0320, and SFN on viability of SIM-A9 cells
As mentioned in the “Materials and Methods” section, the experimental GSK3 inhibitors were
evaluated for their cytotoxicity in SIM-A9 cells via the MTT assay, following the hereinabove
outlined treatment protocol, which uses 10, 20, 40 and 80 micromolar concentrations of each
compound alone or in conjunction with 100 ng/mL LPS. As is evident in Figure 3.3, none of the
compounds was significantly cytotoxic at any of the treatment concentrations, either alone or in
conjunction with LPS. SFN, used as a positive control for countervailing inflammation and Nrf2
activation, was also assayed for its cytotoxicity at the treatment concentrations of 0.5 μM, 1 μM,
5 μM, and 10 μM. Again, cellular viability was sustained across all treatment concentrations.
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Figure 3.3. Effect of BRD0705, BRD3731, BRD0320, and SFN on viability of SIM-A9 cells. Cell viability was assessed using the MTT assay following treatment of
SIM-A9 cells with BRD0705 (GSK3α inhibitor; A), BRD3731 (GSK3β inhibitor; B), BRD0320 (GSK3α/β inhibitor; C), and SFN (D). All experimental compounds were
then reassessed in presence of 100 ng/mL LPS (E-H). Data is expressed as means ± SEM. Group comparisons were drawn using one-way ANOVA, followed by the
Student-Newman-Keuls post-hoc test.

3.4. Effect of different concentrations of LPS on nitrite production in SIM-A9 cells

In order to instigate an inflammatory response in microglial cells, LPS-induced increase of nitric
oxide was evaluated by the Griess method using 3 incrementally increasing concentrations of LPS
of the E. coli O111:B4 strain (10 ng/mL, 100 ng/mL and 1 μg/mL). None of the tested LPS
concentrations was able to induce a significantly observable rise in nitrite production from cells
seeded at densities of 0.5×105 cells/mL or 1×105 cells/mL. However, an obvious and dosedependent rise in nitrite concentration was observed in cells plated at 2.5×105 cells/mL and 5×105
cells/mL seeding densities, which was statistically significant (P-value < 0.05) across all
concentrations. Considering that exposure to LPS at the 1 μg/mL concentrations correlated with
extensive cell death as evidenced by the MTT assay, only the 10 ng/mL and the 100 ng/mL
concentrations were to be comparatively considered for ensuing experiments. LPS at the
concentration 10 ng/mL incited a 1.89-fold (188.65%) and a 3.44-fold (344.39%) upsurge in nitrite
levels in cells plated at the concentrations 2.5×105 cells/mL and 5×105 cells/mL, respectively;
whereas 100 ng/mL LPS increased nitrite production by 3.78-fold (378.38%) and 5.6-fold
(560.43%) in the cellular densities 2.5×105 cells/mL and 5×105 cells/mL, respectively (Figure 3.4).
Taken together, these results along with those obtained from experiments of cell viability
demanded that subsequent experiments be run using LPS at the 100 ng/mL concentration for
stimulation of SIM-A9 cells seeded at a concentration of 5×105 cells/mL.
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Figure 3.4. Effect of different concentrations of LPS on SIM-A9 cells with varying cellular densities. Effect of different
LPS concentrations on nitrite production in SIM-A9 cells seeded at a density of 0.5×105 cells/mL (A), 1×105 cells/mL (B),
2.5×105 cells/mL (C), and 5×105 cells/mL (D). (E) Combined representation of LPS-mediated increase in nitrite production in
SIM-A9 cells seeded at varying densities. Data is expressed as means ± SEM. Comparison of different LPS concentrations for
a given seeding density was drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test. To measure
interactivity of LPS concentrations with varying seeding densities, group comparisons were drawn using two-way ANOVA,
followed by the Student-Newman-Keuls post-hoc test; $ P-value < 0.05 (relative to negative [untreated] controls); * P-value
< 0.05 (LPS concentration at seeding density of 2.5×105 vs same LPS concentration at seeding density of 5×105); • P-value <
0.05 (100 ng/mL LPS vs 10 ng/mL LPS at the same seeding density)
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3.5. Effect of GSK3 inhibitors on nitrite production in LPS-activated SIM-A9 cells
To initially evaluate any potential anti-inflammatory effect associated with the tested GSK3
inhibitors on a functional level, nitrite production was again measured in the cell culture media of
SIM-A9 cells treated with LPS and the GSK3 inhibitor compounds, according to the protocol
previously outlined. In this experiment, LPS significantly increased nitrite levels compared to
control (Figure 3.5). BRD0705 (GSK3α inhibitor) significantly inhibited the LPS-stimulated
production of nitrites by 18.39%, 34.09%, and 35.43% at 10 μM, 20 μM, and 40 μM, respectively.
The GSK3 inhibitor, BRD3731, also significantly inhibited LPS-stimulated nitrite production by
20.12%, 52.78%, and 59.44% at 10 μM, 20 μM, and 40 μM, respectively. The anti-nitrosative
efficacy of the lowest concentration of the GSK3/ inhibitor BRD0320 (10 μM) surpassed the
highest of BRD0705 (GSK3α inhibitor; 40 μM) as it significantly inhibited the LPS-stimulated
production of nitrites by 34.36%. Furthermore, BRD0320 (GSK3α/β inhibitor) significantly
inhibited the LPS-stimulated production of nitrites by 48.41% and 56.11% at 20 μM and 40 μM,
respectively. Differences between the nitrite-lowering efficacy of the 20 μM and 40 μM
concentrations of BRD0705 (GSK3α inhibitor) and BRD3731 (GSK3β inhibitor) were statistically
significant, while only at the highest concentration did BRD0705 (GSK3α inhibitor) and BRD0320
(GSK3α/β inhibitor) exhibit any significant differences. Variations between BRD3731 (GSK3β
inhibitor) and BRD0320 (GSK3α/β inhibitor) were insignificant across all concentrations. Lastly,
SFN significantly inhibited the LPS-stimulated production of nitrites by 98.65% at 5 μM.
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Figure 3.5. Effect of GSK3 inhibitors on nitrite production in LPS-activated SIM-A9 cells. SIM-A9 cell (5×105 cells/mL cell
density) were stimulated with 100 ng/mL LPS for 24 h, in presence of the GSK3 inhibitors (BRD0705, BRD3731, and BRD0320)
and SFN. Nitrite production was measured in the cell culture media using the Griess method. Data is expressed as means ± SEM.
Group comparisons were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05
(relative to the LPS-activated group); $ P-value < 0.05 (relative to negative [untreated] controls); # P-value < 0.05 (BRD0705 at
any given concentration relative to BRD3731 at the corresponding concentration).
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3.6. Effect of GSK3 inhibitors on the mRNA expression of the microglial activation markers
CD11b and Iba1 in LPS-activated SIM-A9 cells

To further investigate the putative anti-inflammatory effects of selective and non-selective
pharmacological GSK3 inhibition, gene expression analysis via quantitative real-time PCR was
performed to assess the mRNA levels of principal proinflammatory genes. First, mRNA levels of
the commonly assessed surface markers of microglial activation CD11b (Ladeby et al., 2005;
Yuskaitis et al., 2009) and Iba1 (Ohsawa et al., 2004) were quantitatively assessed in treatmentnaïve controls and LPS-activated cells, in presence and absence of GSK3 inhibitors, following the
above-described treatment protocol. As shown in Figure 3.6, activation of SIM-A9 microglia by
100 ng/mL LPS resulted in a significant upregulation of CD11b and Iba1. Selective inhibition of
GSK3α by 10 μM and 20 μM BRD0705 lowered the mRNA levels of CD11b by 11.22% and
26.2%, and those of Iba1 by 76.37% and 84.53%, respectively. Non-selective inhibition of GSK3
by BRD0320 correlated with an improved reduction of CD11b and Iba1, compared to GSK3αselective inhibition. CD11b and Iba1 mRNA levels were significantly inhibited by 33.53% and
73.41%, respectively at 10 μM, and by 45.13% and 80.78%, respectively at 20 μM BRD0320
(GSK3α/β inhibitor). GSK3β-selective inhibition by BRD3731 was the most potent suppressor of
the mRNA expression of these microglial activation markers. As such, CD11b mRNA levels were
significantly decreased by 38.11% and 53.23% at 10 μM and 20 μM, respectively. Additionally,
Iba1 mRNA levels were significantly inhibited by 88.58% and 95.48% at 10 μM and 20 μM,
respectively. The dose-dependent amelioration of function was statistically significant for all three
compounds, and at 20 μM, the functional differences between all treatments were statistically
meaningful, with the exception of Iba1 modulation by BRD3731 (GSK3β inhibitor) and BRD0320
(GSK3α/β inhibitor). Finally, SFN at 5 μM significantly inhibited CD11b and Iba1 mRNA levels
by 43.11% and 99.72%, respectively.
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Figure 3.6. Effect of GSK-3 inhibitors on the mRNA expression of the microglial activation markers CD11b and Iba1 in
LPS-activated SIM-A9 cells. Target mRNA expression was quantified by real-time qPCR and normalized to GAPDH. All
compounds show a dose-dependent decrease of the LPS-triggered upregulation of the microglial activation markers CD11b (A)
and Iba1 (B). Data is expressed as means ± SEM. Group comparisons were drawn using one-way ANOVA, followed by the StudentNewman-Keuls post-hoc test; * P-value < 0.05 (relative to the LPS-activated group); $ P-value < 0.05 (relative to negative
[untreated] controls); # P-value < 0.05 (BRD0705 at any given concentration relative to BRD3731 at the corresponding
concentration).
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3.7. Effect of GSK3 inhibitors on the mRNA expression of iNOS in LPS-activated SIM-A9
cells

In verification of results obtained from the Griess assay, iNOS, a major player in inflammatory
and para-inflammatory disorders (Suschek et al., 2004; Xue et al., 2018) was evaluated for its
transcriptional rates in the different treatment groups versus untreated controls. The results are
shown in Figure 3.7. BRD0705 (GSK3α inhibitor) insignificantly inhibited LPS-stimulated iNOS
mRNA levels by 4.82% at 10 μM, and it significantly inhibited iNOS mRNA levels by 28.8% at
20 μM. Dual inhibition of the two GSK3 isoforms by BRD0320 resulted in significant inhibition
of LPS-stimulated iNOS mRNA levels by 23.99% at 10 μM and 31.4% at 20 μM, whereas GSK3βselective inhibition by BRD3731 significantly inhibited iNOS mRNA levels by 26.4% at 10 μM
and 34.38% at 20 μM. As evident in Figure 7, SFN at 5 μM significantly inhibited iNOS mRNA
levels by 97.77%.
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Figure 3.7. Effect of GSK3 inhibitors on the mRNA expression of iNOS in LPS-activated SIM-A9 cells. Target mRNA
expression was quantified by real-time qPCR and normalized to GAPDH. All compounds show a dose-dependent reduction of the
LPS-stimulated upregulation of iNOS. Data is presented as means ± SEM. Group comparisons were drawn using one-way ANOVA,
followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05 (relative to the LPS-activated group); $ P-value < 0.05
(relative to negative [untreated] controls); # P-value < 0.05 (BRD0705 at any given concentration relative to BRD3731 at the
corresponding concentration).
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3.8. Effect of GSK3 inhibitors on the mRNA expression of the proinflammatory cytokines
IL-1β, IL-6 and TNF-α in LPS-activated SIM-A9 cells

Stimulated proinflammatory cytokine signaling is typical of activated microglia and is associated
with neuroinflammation and neurodegenerative proteopathy (W.-Y. Wang et al., 2015). mRNA
expression of the secretory proinflammatory cytokines IL-1β, IL-6, and TNF-α was therefore
performed and echoed the results obtained for CD11b, Iba1, and iNOS. LPS significantly increased
IL-1β, IL-6, and TNF-α mRNA levels. BRD0705 (GSK3α inhibitor) significantly inhibited IL-1β
mRNA levels by 48.09% and 59.22% at 10 μM and 20 μM, respectively. Importantly, BRD3731
(GSK3β inhibitor) significantly inhibited IL-1β mRNA levels by 75.67% and 92.75% at 10 μM
and 20 μM, respectively. Additionally, BRD0320 (GSK3α/β inhibitor) significantly inhibited IL1β mRNA levels by 73.41% and 80.78% at 10 μM and 20 μM, respectively. SFN significantly
inhibited IL-1β mRNA levels by 97.17% at 5 μM. The same trend was observed for IL-6;
BRD0705 (GSK3α inhibitor) significantly inhibited IL-6 mRNA levels by 14.26% and 26.69% at
10 μM and 20 μM, respectively. BRD3731 (GSK3β inhibitor) significantly inhibited IL-6 mRNA
levels by 42.14% and 54.57% at 10 μM and 20 μM, respectively. BRD0320 (GSK3α/β inhibitor)
significantly inhibited IL-6 mRNA levels by 32.29% and 43.06% at 10 μM and 20 μM,
respectively, whereas SFN significantly inhibited IL-6 mRNA levels by 91.92% at 5 μM.
Post-treatment TNF-α transcriptional modulation followed a similar course. TNF-α levels dropped
by 40.8% and 62.87% following BRD3731 (GSK3β inhibitor) treatment at 10 μM and 20 μM,
respectively. BRD0320 (GSK3α/β inhibitor) lowered LPS-exacerbated TNF-α levels by 34.55%
at 10 μM and by 52.66% at 20 μM, while BRD0705 (GSK3α inhibitor) brought on a 17.94%
decline in TNF-α transcripts at 10 μM, almost doubling to 37.6% at 20 μM. A 70.51% reduction
in TNF-α levels was registered for SFN (5 μM). The evident dose-dependency was statistically
powerful as relayed by the analysis of data retrieved for the 10 μM and 20 μM concentrations. The
functional differences between BRD0705 (GSK3α inhibitor) and BRD3731 (GSK3β inhibitor)
were also significant, from a statistical standpoint. Only for TNF-α, the modulatory variance
between BRD0705 (GSK3α inhibitor) and BRD0320 (GSK3α/β inhibitor) was, however, not
statistically significant (Figure 3.8).
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Figure 3.8. Effect of GSK3 inhibitors on the mRNA expression of the proinflammatory cytokines IL-1β, IL-6 and TNFα in LPS-activated SIM-A9 cells. Target mRNA expression was quantified by real-time qPCR and normalized to GAPDH.
All compounds manifest a dose-dependent moderation of the LPS-induced escalation of the proinflammatory cytokines IL-1β
(A), IL-6 (B), and TNF-α (C). Results shown are represented as means ± SEM. Group comparisons were drawn using one-way
ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05 (relative to the LPS-activated group); $ Pvalue < 0.05 (relative to negative [untreated] controls); # P-value < 0.05 (BRD0705 at any given concentration relative to
BRD3731 at the corresponding concentration).
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3.9. Effect of GSK3 inhibitors on the mRNA expression of Nrf2-driven ARE genes HO-1 and
Osgin1 in LPS-activated SIM-A9 cells

In order to evaluate the effects of selective suppression of the individual GSK3 paralogs on
mediating Nrf2 transcriptional activation, the mRNA expression of two ARE genes, HO-1 and
Osgin1, was quantified by real-time PCR, following treatment with the GSK3 inhibitors, under the
supposition that Nrf2 destabilization and nuclear localization should translate to enhanced
transcription of its target genes. The results are shown in Figure 3.9. BRD3731 (GSK3β inhibitor)
was the most potent Nrf2 activator; it induced a 36.56% enhancement of HO-1 expression at 10
μM and 73.99% at 20 μM, compared to untreated LPS-stimulated microglia. Osgin1 mRNA
expression was similarly enhanced by 125.69% at 10 μM BRD3731 (GSK3β inhibitor) and by
237.19% at 20 μM. BRD0320 (GSK3 α/β inhibitor) increased HO-1 mRNA expression by 38.21%
and 43.86% at 10 μM and 20 μM, respectively, whereas these concentrations brought about a
144.52% and a 175.08% increase in Osgin1 mRNA levels. BRD0705 (GSK3α inhibitor) at 10 μM
treatment stimulated HO-1 transcription by 10.89% and by 22.66% at 20 μM. Osgin1 expression
was upraised by 58.56% at the 10 μM concentration and by 67.87% at the 20 μM concentration.
With BRD0705 (GSK3α inhibitor), dose variations were of no statistical import for either target,
neither were the differences in functional competency with BRD0320 (GSK3α/β inhibitor) for
HO-1.
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Figure 3.9. Effect of GSK3 inhibitors on the mRNA expression of the Nrf2-driven ARE genes HO-1 and Osgin1 in
LPS-activated SIM-A9 cells. Target mRNA expression was quantified by real-time qPCR and normalized to GAPDH. All
GSK3 inhibitor treatments – except for BRD0705 (GSK3α inhibitor) at 10 μM – show a statistically significant upregulation
of the Nrf2-driven ARE gene HO-1 (A) and all treatments – without exceptions – correlate with a rise in Osgin1 mRNA
levels (B). BRD3731 (GSK3β inhibitor) displays the greatest Nrf2-inducing activity after the positive control (SFN; 5 μM),
followed by BRD0320 (GSK3α/ β inhibitor), then BRD0705 (GSK3α inhibitor). Data is expressed as means ± SEM. Group
comparisons were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05
(relative to the LPS-activated group); $ P-value < 0.05 (relative to negative [untreated] controls); # P-value < 0.05 (BRD0705
at any given concentration relative to BRD3731 at the corresponding concentration).
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3.10. Effect of GSK3 inhibitors on the mRNA expression of the β-catenin-transcribed c-Myc
in LPS-activated SIM-A9 cells
Given empirical evidence suggesting isoform-distinctive β-catenin regulatory profiles (Wagner et
al., 2018) and other data herein cited (see Discussion) that pinpoints the involvement of β-catenin
in our pathophysiological context of interest, we set out to evaluate c-Myc mRNA levels, a
transcriptional target of Wnt/β-catenin signaling pathway (Herbst et al., 2014). LPS alone incited
a 404.79% rise in c-Myc levels. BRD0705 (GSK3α inhibitor) elaborated on this increase by 8.29%
(446.61% overall increase relative to untreated controls) at 10 μM and by 12.81% (469.46%
overall increase relative to untreated controls) at 20 μM. Selective inhibition of GSK3β by
BRD3731 displayed the most β-catenin destabilization, as shown by the elevated c-Myc mRNA
levels; BRD3731 (GSK3β inhibitor) upregulated c-Myc by 1,399.93% at 10 μM and by 2,086.86%
at 20 μM, relative to untreated controls. This trend translates to a 197.14% and a 333.22% increase
in c-Myc expression at 10 and 20 μM, respectively, compared to cells solely treated with LPS.
Non-selective GSK3 inhibition by BRD0320 promoted c-Myc transcription by 1,031.67% at 10
μM and 1,376.07% at 20 μM, compared to untreated controls (124.19% and 192.41% relative to
LPS-stimulated cells). Coupling the insignificance of dose-dependent biological outcome, no
statistical significance was demonstrable between the two concentrations of BRD0705 (GSK3α
inhibitor). Nonetheless, variations in the pattern of c-Myc mRNA expression were significant
statistically across all three compounds, wherever comparisons between matched concentrations
were made. Results are shown in Figure 3.10.
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Figure 3.10. Effect of GSK3 inhibitors on the mRNA expression of the β-catenin−transcribed c-Myc in LPS-activated SIMA9 cells. Target mRNA expression was quantified by real-time qPCR and normalized to GAPDH. Only BRD3731 and BRD0320
show a statistically significant augmentation of c-Myc transcription. BRD3731 (GSK3β inhibitor) displays the most βcatenin−inducing activity followed by BRD0320 (GSK3α/β inhibitor). BRD0705 (GSK3α inhibitor) does not induce any
considerable change in c-Myc expression beyond that which is already occasioned by LPS alone. Data is expressed as means ±
SEM. Group comparisons were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value
< 0.05 (relative to the LPS-activated group); # P-value < 0.05 (BRD0705 at any given concentration relative to BRD3731 at the
corresponding concentration).
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3.11. Effect of GSK3 inhibitors on the protein levels of the proinflammatory cytokines IL1β, IL-6 and TNF-α in LPS-activated SIM-A9 cells

To confirm that the anti-inflammatory responses observed on the mRNA level carried through to
the protein level, the protein concentrations of the secretory proinflammatory cytokines IL-1β, IL6 and TNF-α were evaluated by ELISA in the cell culture supernatant. LPS (100 ng/mL) promoted
the proinflammatory profile of SIM-A9 cells as reflected by the elevated protein levels of the
evaluated cytokines (Figure 3.11). At 20 μM, BRD0705 (GSK3α inhibitor) reduced the LPSmediated increase of IL-1β by 24.33%, IL-6 by 34.67%, and TNF-α by 14.9%. At the same
concentration, BRD3731 (GSK3β inhibitor) reduced IL-1β by 89.57%, IL-6 by 47.85% and TNFα by 74.62%. Dual inhibition of the two GSK3 isoforms by BRD0320 at 20 μM corresponded with
59.27%, 39.33%, and 54.01% reduction in LPS-elevated IL-1β, IL-6, and TNF-α proteins,
respectively. Statistical analysis inferred the significance of all changes noted between the
compounds, excepting the instance of comparing BRD0705 (GSK3α inhibitor) and BRD0320
(GSK3α/β inhibitor) within the IL-6 assay.
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Figure 3.11. Effect of GSK3 inhibitors on the protein levels of the proinflammatory cytokines IL-1β, IL-6 and TNF-α
in LPS-activated SIM-A9 cells. All compounds show a statistically significant reduction of the LPS-stimulated upregulation
of the proinflammatory cytokines IL-1β (A), IL-6 (B), and TNF-α (C). Data is expressed as means ± SEM. Group comparisons
were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05 (relative to the
LPS-activated group); $ P-value < 0.05 (relative to negative [untreated] controls); # P-value < 0.05 (BRD0705 at any given
concentration relative to BRD3731 at the corresponding concentration).
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3.12. Effect of GSK3 inhibitors on the nuclear translocation of Nrf2, β-catenin, and the p65
subunit of NF-κB in LPS-activated SIM-A9 cells

To probe into the mechanistic underpinnings of the observed anti-inflammatory and anti-oxidative
effects of GSK3 inhibition, nuclear protein lysates extracted from treated SIM-A9 cells were
analyzed by immunoblotting for a quantitative assessment of the levels of Nrf2 and NF-κB p65 in
the nucleus. The experiment was to inform whether the modulatory effects of GSK3 inhibition
occur via facilitating the translocation of Nrf2 and the p65 subunit of NK-κB into the nuclear
compartment, thereby promoting the transcription of their downstream targets. Figure 3.12 shows
images of the immunoblots and the derived graphical representations outlining the treatmentassociated modulatory trends. Nrf2 immunoblots revealed an 86.83% increase in nuclear Nrf2 in
LPS-stimulated cells concurrently treated with the GSK3β inhibitor, BRD3731 (118.04% increase
relative to untreated controls). LPS-stimulated cells treated with the non-selective GSK3 inhibitor,
BRD0320, demonstrated a 61.4% increase in nuclear Nrf2 (88.36% increase relative to untreated
controls), while BRD0705 (GSK3α inhibitor) raised the nuclear content of Nrf2 by 39.34%
compared to cells treated with LPS only (62.62% more than the nuclear Nrf2 levels of untreated
controls). SFN, an established electrophilic activator of Nrf2, brought about a 67.06% increase in
nuclear Nrf2 compared to LPS-stimulated cells and a 94.97% increase compared to untreated
controls. NF-κB immunoblots displayed a contrary trend, where GSK3 inhibition correlated with
diminished nuclear levels of NF-κB p65. LPS-stimulated SIM-A9 microglia accumulated more
NF-κB p65 in their nuclei (64.17% increase); SFN lowered this augmentation by 74.44%. Again,
GSK3β inhibition by BRD3731 exhibited an unmatched anti-inflammatory tendency with an
82.69% drop in nuclear NF-κB p65. Pan-inhibition of GSK3 by BRD0320 in LPS-stimulated cells
correlated with a 35.32% decrease in nuclear NF-κB p65. BRD0705 (GSK3α inhibitor) had almost
no effect on NF-κB p65 nuclear translocation, with only a 4.01% reduction in the nuclear content
of the p65 subunit. Unlike the discrepancy above outlined for Nrf2, the functional unevenness
displayed by the densitometric analysis was substantiated by the statistical analysis of the data,
where differences between BRD0705 (GSK3α inhibitor) and BRD3731 (GSK3β inhibitor) were
statistically meaningful, as well as BRD3731 (GSK3β inhibitor) and BRD0320 (GSK3α/β
inhibitor). Wherever comparisons were drawn between BRD0705 (GSK3α inhibitor) and
BRD0320 (GSK3α/β inhibitor), differences therewith were determined to be statistically
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inconsequential. The same statistical outcome was replicated in the analysis of data from β-catenin
blots, where BRD3731 (GSK3β inhibitor) was the only GSK3 inhibitor to mediate a significant
increase of β-catenin in the nucleus.
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Figure 3.12. Effect of GSK3 inhibitors on the nuclear translocation of Nrf2, β-catenin, and the p65 subunit of NF-κB
in LPS-stimulated SIM-A9 cells. Western immunoblots and derived graphical representation of the protein expression pattern
for Nrf2 (A), NF-κB p65 (B), and β-catenin (C) are shown. Data is expressed as means ± SEM. Group comparisons were
drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05 (relative to the LPSstimulated group); $ P-value < 0.05 (relative to negative [untreated] controls) ; # P-value < 0.05 (BRD0705 at any given
concentration relative to BRD3731 at the corresponding concentration).
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3.13. Efficiency of DsiRNA-mediated transfection of SIM-A9 cells

To determine whether the anti-inflammatory effect of the GSK-3 inhibitors was Nrf2-dependent,
DsiRNA-mediated knockdown of Nrf2 was pursued as described in the “Materials and methods”
section. Robustness of the transfection protocol was ascertained in two ways; first, SIM-A9 cells
were reverse-transfected with a transfection control DsiRNA, tagged with TYE 563. As evident in
Figure 3.13.1A and Figure 3.13.1B, only transfected cells showed fluorescence as soon as 6 h posttransfection in comparison with non-transfected control cells. Transfected cells were noted to
exhibit an elongated shape rather than the predominantly rounded morphology of their nontransfected counterparts. For a quantitative assessment of transfection efficiency, an HPRTtargeting positive control DsiRNA was transduced into the cells; HPRT mRNA expression was
thereafter assessed, 24 hr post-transfection. In cells transfected with the positive control DsiRNA,
HPRT was silenced by 93.33% compared to cells transfected with a non-targeting negative control
DsiRNA (Figure 3.13.1C). Following the same protocol, in two separate experiments, successful
knockdown of Nrf2 was achieved in treatment-naïve cells, as indicated by post-transfection qPCR,
with an efficiency of 87.26% (Figure 3.13.1D) and 88.47% (Figure 3.13.2) compared to cells
transfected with a non-targeting negative control DsiRNA (Figure 3.13.1D). Knockdown
efficiency across all treatment groups were subsequently determined and ranged between 81.39%
to 88.47% (Figure 3.13.2).
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Figure 3.13.1. Efficiency of DsiRNA-mediated transfection of SIM-A9 cells. Qualitative evaluation of the transfection protocol
shows fluorescence of cells transfected with TYE 563-tagged DsiRNA (A) as opposed to untransfected cells (B), which do not
manifest any discernable fluorescence. Efficiency of transfection was gauged by quantitative measurement of HPRT mRNA
expression, following transduction of cells with the positive control HPRT-targeting DsiRNA (C). Silencing of Nrf2 was similarly
confirmed by qPCR (D), following transfection of Nrf2-targeting DsiRNAs into cells. Data is expressed as means ± SEM. Group
comparisons were drawn using Welch's t-test; * P-value < 0.05 (relative to the NTC group).
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Figure 3.13.2. Knockdown efficiency of Nrf2 in DsiNrf2-transfected SIM-A9 cells. Real-time qPCR data showing the
expression of Nrf2 in DsiNrf2-transfected SIM-A9 cells relative to their DsiNTC-transfected controls. Nrf2 knockdown efficiency
in the DsiNrf2-transfected cells is expressed as the % decrease of Nrf2 expression in the corresponding siNTC-transfected cells.
Data is expressed as means ± SEM. Comparisons between each DsiNTC and its respective DsiNrf2 were drawn using Welch's ttest; * P-value < 0.05 (relative to the DsiNTC group).
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3.14. Effect of GSK3 inhibitors on the mRNA expression of Nrf2-driven ARE genes HO-1
and Osgin1 in DsiNrf2-transfected, LPS-activated SIM-A9 cells

As explained above, Nrf2 mRNA expression was determined to considerably drop, following
DsiNrf2-mediated gene silencing. To confirm a corresponding transcriptional restriction of ARE
genes, HO-1 and Osgin1 were re-assessed by qPCR, following knockdown of their transcriptional
activator. The generated qPCR data suggests that there was no significant difference in HO-1 and
Osgin1 mRNA expression between untreated controls, LPS-activated and LPS/GSK-3 inhibitortreated groups (Figure 3.14). As with previous qPCR experiments, the Nrf2-activating capability
of the GSK3 inhibitors was assessed in the proinflammatory (LPS-activated) context, i.e.,
expression in the GSK3 inhibitor-treated groups was compared to the LPS-activated group, rather
than the untreated controls.
In the cells in which Nrf2 was silenced (DsiNrf2 group), BRD0705 (GSK3α inhibitor)-mediated
induction of HO-1 and Osgin1 was reduced by 34.4% and 18.94%, respectively, relative to groups
receiving a non-targeting negative control DsiRNA (DsiNTC). The Nrf2-inducing activity of
BRD3731 (GSK3β inhibitor) noted in the DsiNTC group (122.73% increase in HO-1 and 152.42%
increase in Osgin1) was likewise compromised by 119.51% for HO-1 and by 151% for Osgin1 in
the DsiNrf2 group. BRD0320 (GSK3α/β inhibitor) also lost its Nrf2-activating functionality as
evidenced by a 66.37% and a 69.81% drop in HO-1 and Osgin1 mRNA expression, respectively.
SFN, a well-recognized Nrf2 activator, lost its ability to induce these Nrf2 targets by 195.12% for
HO-1 and 348.82% for Osgin1, a substantial reversal of effect, given its remarkable efficacy in
stimulating the transcription of these targets in the DsiNTC group (198.1% and 350.3%
upregulation of HO-1 and Osgin1, respectively). Collectively, a loss of the anti-oxidative
upregulation of HO-1 and Osgin1 by the GSK3 inhibitors was noted in Nrf2 knockdowns
(DsiNrf2) compared to controls (DsiNTC).
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Figure 3.14. Effect of GSK3 inhibitors on the mRNA expression of Nrf2-driven ARE genes HO-1 and Osgin1 in DsiNrf2transfected, LPS-activated SIM-A9 cells. Both HO-1 (A) and Osgin1 (B) only exhibit basal levels of expression following
knockdown of Nrf2 and are not affected by any of the treatments in any manner of significance. Data is expressed as means ± SEM.
Group comparisons were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test, and relay no
intergroup statistical significance (P-value > 0.05).
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3.15. Effect of GSK3 inhibitors on the mRNA expression of the proinflammatory mediators
iNOS, IL-1β, IL-6 and TNF-α in DsiNrf2-transfected, LPS-stimulated SIM-A9 cells.

Having confirmed post-knockdown transcriptional suppression of Nrf2-driven genes, transcripts
for proinflammatory genes were quantified by qPCR in the DsiNrf2 groups to determine whether
Nrf2 silencing would compromise the above-proven anti-inflammatory function of the GSK3
inhibitors. Overall, previously relayed expression patterns remained unchanged. Reduction of
iNOS mRNA expression in the DsiNrf2 group amounting to only 3.26% (BRD0705; GSK3α
inhibitor), 2.34% (BRD3731; GSK3β inhibitor), 1.68% (BRD0320; GSK3α/β inhibitor) and
2.64% (SFN) of corresponding expression trends in the DsiNTC group suggested no overlap
between GSK3-mediated Nrf2 activation and its repressive influence on iNOS transcription
(Figure 3.15). Comparisons of treatment groups in which Nrf2 was silenced (DsiNrf2) and those
in which Nrf2 expression was maintained at its basal levels (DsiNTC) determined lack of any
statistical significance of the observed intergroup changes, while analysis of variations across
treatments confirmed the soundness of thus far proven BRD3731 (GSK3β inhibitor) superiority to
BRD0705 (GSK3α inhibitor) and BRD0320 (GSK3α/β inhibitor).
Conforming to the preceding modulatory tendency, transcription rates for IL-1β, IL-6 and TNF-α
were largely analogous between the DsiNrf2 and DsiNTC groups (Figure 3.15). This was
demonstrable by both the statistical and biological insignificance of the expression pattern
differences between both groups. The GSK3 inhibitors comparably reversed LPS-augmented
mRNA levels of the screened proinflammatory cytokines. IL-1β mRNA expression in the DsiNrf2
group only decreased by 1.68% (BRD0705; GSK3α inhibitor), 2.71% (BRD3731; GSK3β
inhibitor), 2.71% (BRD0320; GSK3α/β inhibitor), and 0.04% (SFN), compared to the DsiNTC
group. In relation to the DsiNTC group, levels of IL-6 mRNA in the DsiNrf2 group merely differed
by 2.94% (BRD0705; GSK3α inhibitor), 2.65% (BRD3731; GSK3β inhibitor), 7.7% (BRD0320;
GSK3α/β inhibitor), and 3.59% (SFN). The DsiNTC group came ahead of the DsiNrf2 group with
only 1.15% (BRD0705; GSK3α inhibitor), 4.87% (BRD3731; GSK3β inhibitor), 2.03%
(BRD0320), and 3.18% (SFN) higher TNF-α mRNA expression. Collectively and unlike
observations made with the anti-oxidative genes HO-1 and Osgin1, the anti-inflammatory effects
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of GSK3 inhibition were unaffected by Nrf2 silencing, as conveyed by the consistent expression
patterns of proinflammatory markers between the DsiNrf2 and DsiNTC groups. Comparisons
drawn between BRD0705 (GSK3α inhibitor), BRD3731 (GSK3β inhibitor) and BRD0320
(GSK3α/β inhibitor) once again informed of the statistical import of the differences detected
therewith.
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Figure 3.15. Effect of GSK3 inhibitors on the mRNA expression of the proinflammatory mediators iNOS, IL-1β, IL-6 and
TNF-α in DsiNrf2-transfected, LPS-stimulated SIM-A9 cells. Target mRNA expression was quantified by real-time qPCR and
normalized to HPRT. GSK3 inhibitors are shown to maintain the same pre-knockdown modulatory pattern of iNOS (A), IL-1β (B),
IL-6 (C) and TNF-α (D) expression, following Nrf2 knockdown. No significance, biological or statistical, was observed between
the modulatory trends effected by GSK3 inhibitors in DsiNrf2 vs DsiNTC. Data is expressed as means ± SEM. Group comparisons
were drawn using one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test; * P-value < 0.05 (relative to the LPSstimulated group); $ P-value < 0.05 (relative to negative [untreated] controls); # P-value < 0.05 (BRD0705 at any given
concentration relative to BRD3731 at the corresponding concentration).
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4. DISCUSSION

Neuroinflammatory glial responses are a central component and often an inciting factor of
degenerative changes in the CNS. Oxidative stress and accompanying low-grade chronic
inflammation lie at the heart of the oxidative, para-inflammatory paradigm of aging and has been
recently recognized as a significant yet largely overlooked pathophysiological arm of NDs.
Microglia are the primary line of defense of the innate immunity in the CNS and their deprivation
of hematopoietic renewal renders them particularly vulnerable to stress-induced senescence and
consequent pro-degenerative deregulation of their housekeeping role. As extensively explained
above, microglia have been implicated in the pathophysiological underpinnings of the most
notorious NDs. Chronically activated and oxidatively stressed microglia are major aggravators of
degenerative neuronal damage and their frequently exaggerated proinflammatory response often
results in further disease dissemination leading to further glial dysfunction and worsening of
neuronal detrition. In theory, this anomalous proinflammatory stance can either originate in
microglia and go on to engender neuronal damage or may occur in consequence of neuronal
pathology, which microglial incompetence can then exacerbate and end up further propagating in
their fraught attempts to clear the pathological stimulus. As it happens, the heterogeneity of
microglial subsets and the constant and elaborate crosstalk between neural subsets is too complex
to draw clear-cut etiological models or isolate a single directional sequence of events with any
degree of certainty. Modulation of activated microglial subsets, however, constitutes an
increasingly sought after mitigative strategy, irrespective of the etiological precedence of
pathological changes within microglia.

GSK3 has been recognized as the principal kinase to mediate tau hyperphosphorylation as well as
– albeit not as fundamentally – amyloidopathy in neurons. Additionally, it has been proven to
encourage the frenetic proinflammatory alias of microglia. This is particularly germane within
chronically stressed microglia. Given that GSK3 is one of the key negative regulators of Nrf2, the
redox master of the cell, the regulatory loop therein poses great relevance to the involvement of
GSK3 in NDs, not just through its proteopathic influence, but by way of instigating oxidative stress
in microglial cells. Moreover, the molecular cooperativity between GSK3 and NF-κB, a major
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inflammatory player, and the inverse relationship between the latter and Nrf2 suggests a prooxidative, proinflammatory GSK3/NF-κB/Nrf2 regulatory loop.

As such, we theorized that inhibitory targeting of GSK3 could pose a multimodal therapeutic
strategy in NDs, since not only will it check the production of toxic protein forms, but also, it
should activate counter-oxidative mechanisms and repress subcellular inflammatory processes in
neurons and neuroglia. It was under this conception that we sought to explore the effects of GSK3
inhibition in activated microglia in relation to NF-κB and Nrf2. Moreover, driven by the lack of
research endeavors characterizing the functional differences between GSK3 isoforms, especially
in relation to microglial Nrf2 activation and NF-κB-driven inflammation, we aimed to explore the
differences between selective inhibition of these isoforms in terms of anti-oxidative and antiinflammatory potential.

We chose a simple but reliable in vitro model for a reductionistic examination of the differences
between such paralog-selective inhibition. Unlike microglial cell lines generated via viral
transduction, such as BV2 and N9, SIM-A9 cells are spontaneously immortalized microglia
derived from murine cerebral cortices (Nagamoto-Combs et al., 2014). SIM-A9 cells were found
to retain microglial features for up to 40 passages (Dave et al., 2020), without genetic or
pharmacological manipulation (Nagamoto-Combs et al., 2014). Given the above and as per various
reports herein cited as well as the American Type Culture Collection (ATCC), SIM-A9 cells are
expected to better emulate primary microglia than their virally or pharmacologically transformed
counterparts (Nagamoto-Combs et al., 2014). LPS has been previously used to activate microglia
and promote p-tau in animal models of AD (Desforges et al., 2012) and was therefore used as an
alternative to recombinant cytotoxic tau oligomers to stimulate activation of SIM-A9 cells in this
study, while still maintaining pertinence to the pathological context in question.

A patented GSK3 inhibitor kit developed by a team at Broad Institute Inc. (Wagner et al., 2018)
was used for paralog-selective inhibition of GSK3, where BRD0705 was used as a GSK3αselective inhibitor, BRD3731 served as our GSK3β-selective inhibitor and BRD0320 employed
for non-selective inhibition of GSK3. As the traditional go-to positive control for Nrf2 activation,
SFN was chosen for the purpose in this study. Based on previous work in our lab (Saleh et al.,
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2021), a concentration of 5 μM was used as a positive control for an anti-inflammatory treatment
as well.

First, viability of SIM-A9 cells was assessed by the MTT assay following a 24 h incubation with
the investigational compounds to determine non-cytotoxic concentrations. The range of
concentrations used was decided based on the original published work in which these compounds
were tested. As such, viability was determined at the 10 μM, 20 μM, 40 μM and 80 μM
concentrations. The 80 μM concentration was not to be tested beyond viability experiments, since
it was reported to be the threshold concentration at which the compounds lose paralog-specificity
(Wagner et al., 2018); it was, however, included in the MTT assays to widen the breadth of the
therapeutic window of the compounds and corroborate the safety of lower concentrations, with
relative certainty. As evident by the results, none of the compounds showed any meaningful
cytotoxicity with maximal loss of viability recorded for 80 μM BRD3731 (GSK3β inhibitor) at
6.17% (93.83% viability compared to untreated controls).

To determine the LPS concentration that correlated with maximal microglial activation and the
least cytotoxicity, incrementally increasing concentrations of LPS (10 ng/mL, 100 ng/mL, 1
μg/mL) were evaluated by the MTT assay for cytotoxicity following measurement of cellular
nitrite production on exposure to LPS, which was employed as a provisional prefiguration for
microglial activation. SIM-A9 cells seeded at densities of 0.5×105 cells/mL and 1×105 cells/mL
were found to be largely unresponsive to LPS at all concentrations. Therefore, and again informed
by previous results from our lab (Saleh et al., 2021), we opted to optimize cellular concentrations,
evaluating nitrite concentration and hence microglial activation at cellular densities of 2.5×105
cells/mL and 5×105 cells/mL. Overall, variability of both the seeding density and LPS
concentrations significantly affected the activation of SIM-A9 cells as revealed by our analysis,
where the interaction of the two factors accounted for 20.72% of the total variance. According to
our statistical analysis of the data, there was less than 0.01% chance of observing so much
interaction in an experiment of this size (P-value < 0.0001) or bigger. LPS was determined to
account for 27.31% of the total variance, while seeding density accounted for 51.35%. As
demonstrated in Figure 3.4, a cell density of 5×105 cells/mL correlated with the highest response
to LPS stimulation. While 10 ng/mL LPS was sufficient to occasion a significant rise in nitrite
79

concentration, a dose-dependent effect was noted as observed by the nitrite production levels
recorded for the 100 ng/mL (560.43% increase in nitrite) and 1 μg/mL (650.8% increase in nitrite)
concentrations. Given that LPS was significantly cytotoxic to SIM-A9 cells at 1 μg/mL (46.75%
drop in cell viability), LPS at a concentration of 100 ng/mL was chosen to stimulate microglial
activation throughout the rest of the study. To yet ensure uncompromised cellular viability
following the intended experimental protocol, the cytotoxicity of treatment cocktails comprising
100 ng/mL LPS in addition to 10 μM, 20 μM, or 40 μM GSK3 inhibitors or 5 μM SFN was
evaluated and, once again, no cytotoxicity was evident in any of the treatment groups.

Next, we proceeded to examine the nitrite-lowering effect of GSK3 inhibitors following microglial
activation by LPS. Cells were pretreated with GSK3 inhibitors or SFN for 2 h before LPS exposure
to give the compounds a head start (Eléonore Beurel & Jope, 2010; McAlpine & Werstuck, 2014;
Park et al., 2014; M.-J. Wang et al., 2010), in order that repression of GSK3 can be permitted to
take effect and the resultant signaling changes are not clouded by acute TLR4 stimulation.
Following the 2 h pretreatment, the concentrations of the GSK3 compounds were maintained but
LPS was included at a concentration of 100 ng/mL and the cells incubated for additional 24 h.
BRD3731 (GSK3β inhibitor) was associated with a superlative nitrite-reducing competency,
followed by BRD0705 (GSK3α inhibitor) and BRD0320 (GSK3α/β inhibitor). Beyond the lowest
treatment concentration, the anti-nitrosative activity significantly varied between BRD0705
(GSK3α inhibitor) and BRD3731 (GSK3β inhibitor), which constitutes preliminary empirical
evidence of BRD3731 functional precedency. Comparisons between BRD3731 (GSK3β inhibitor)
and BRD0320 (GSK3α/β inhibitor) were not suggestive of a substantial difference in nitritereducing capacity due to paralog selectivity, and only at the highest treatment concentrations were
differences between BRD0705 (GSK3α inhibitor) and BRD0320 (GSK3α/β inhibitor) determined
of statistical import. These results entail that a threshold level of GSK3β inhibition is imperative
for a functional drop in nitrite. Therewith, while the differences in the nitrite-extenuating efficiency
of each compound was manifest and statistically significant between the 10 μM and 20 μM
concentrations, no meaningful variation in potency was noted between the 20 μM and 40 μM
concentrations with any of the treatments. Therefore, we chose to eliminate the 40 μM
concentration from subsequent experiments and only proceed with the 10 μM and 20 μM
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concentrations, which essentially emulates the pioneering study in which these compounds were
first biologically characterized (Wagner et al., 2018).

To further conceive of the anti-inflammatory potential of paralog-selective GSK3 inhibition, we
set out to quantitate the transcriptional rates of several proinflammatory genes using real-time
polymerase chain reaction. Firstly, the mRNA expression levels of the microglial markers CD11b
(Ladeby et al., 2005; Yuskaitis et al., 2009) and Iba1 (Ohsawa et al., 2004) were determined in
each treatment group. We registered a significant dose-dependent decrement of the LPSaggravated upregulation of these markers, which complied with the modulatory trend erstwhile
noted, where BRD3731 (GSK3β inhibitor) was the most competent suppressor of LPS-induced
proinflammatory upset. Following BRD3731, non-selective GSK3 inhibition by BRD0320
manifested a midrange modulation of these markers and BRD0705 (GSK3α inhibitor) showed the
least, albeit statistically significant – and biologically non-negligible – reductive potential. The
same regulatory pattern† was noted with all the other inflammatory markers, namely iNOS, IL-1β,
IL-6, and TNF-α. Our observations agree with earlier work, herein cited, that specifically
recognizes GSK3β as the isoform forward-steering inflammatory responses; while maintaining the
reliability of regulatory models in which GSK3α is central, such as findings by McAlpine and
colleagues, which specify that deletion of GSK3α in myeloid cells promotes an activated “M2”
phenotype (Mcalpine et al., 2015).

We next proceeded with transcript quantitation by qPCR to weigh up the effect of BRD0705
(GSK3α inhibitor), BRD3731 (GSK3β inhibitor) and BRD0320 (GSK3α/β inhibitor) on activating
the transcription of the ARE genes, HO-1 and Osgin1. A reversal of the modulatory tendency was
observed, where BRD3731 (GSK3β inhibitor) brought on the highest mRNA expression levels for
these genes, followed by BRD0320 (GSK3α/β inhibitor) and then BRD0705 (GSK3α inhibitor).
Analysis of all qPCR data indicated that the functional supremacy posed by BRD3731-mediated
GSK3β-selective inhibition constituted a statistically robust paradigm. Again, our findings echo
†

On a general note, the regulatory competency of GSK3 inhibitors differed from one marker to another, where a
compound could prompt substantial changes in one molecule, but only a slight alteration in another. However, and
despite the unevenness within, the pattern of regulation held across all experiments, with BRD3731 (GSK3β inhibitor)
always displaying the most potency. Such discrepancies, while necessitate a deeper understanding of the mechanistic
basis of action for these compounds, are not atypical of GSK3 inhibition (Yuskaitis et al., 2009).
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earlier reports, such as work by Cuadrado et al., that recognize GSK3β, rather than GSK3α, as a
non-canonical negative regulator of Nrf2, via transcriptional activation of the ARE genes HO-1
and Osgin1 (Cuadrado, Kügler, et al., 2018).
According to Wagner, Stegmaier and colleagues, BRD0705, the GSK3α-selective inhibitor, did
not affect β-catenin stabilization and was associated with interrupted β-catenin signaling (Wagner
et al., 2018). Given the reported coincidence of β-catenin and Nrf2 deregulation in a number of
neurodegenerative contexts (Gendy et al., 2021), documented co-dependency (Bianca Marchetti,
2020), the interplay between the Wnt/β-catenin and NF-κB signaling (B. Ma & Hottiger, 2016)
and another loop involving the LPS-responsive TLR4 (Zolezzi & Inestrosa, 2017) – particularly
in our investigated pathological context (Jia et al., 2019; Orellana et al., 2015) and proposed
mechanistic model (Gendy et al., 2021) – we opted to investigate the activity of this transcription
factor in response to our treatments. We aimed to verify the variability between the GSK3 isoforms
on grounds of which these compounds were designed and which pose an added advantage in a
number of disease groups, in which co-morbidities can be of concern. As such, c-Myc, a target
gene of the Wnt/β-catenin signaling (Herbst et al., 2014) was quantitatively assessed by qPCR.
GSK3β inhibition was found to be crucial to nuclear accumulation of β-catenin as can be
extrapolated from the marked c-Myc upregulation (as well as the densitometric patterning from
immunoblots of β-catenin) following BRD3731 (GSK3β inhibitor) treatment. BRD0320
(GSK3α/β inhibitor) was comparatively delimited in mediating nuclear translocation of β-catenin,
and BRD0705 (GSK3α inhibitor) failed to promote any tangible increase. These findings were
circumsubstantiated by statistical analysis of the data, which indicated the significance of the
functional distinctions observed between BRD0705 (GSK3α inhibitor) and BRD3731 (GSK3β
inhibitor). Thereafter, and having formulated a picture of the proinflammatory and oxidative
transcriptional landscape following our treatment protocol, we transitioned to assess the replication
of the results on the protein level. For purposes of pragmatism, only the higher concentration (20
μM) of each compound was used for all experiments onwards.
Post-treatment protein levels of the proinflammatory cytokines IL-1β, IL-6, and TNF-α were
assayed via ELISA. Through optimization experiments, the cell culture supernatant was
determined to contain IL-1β in sparse amounts that any dilution rendered the protein content below
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the detection limit of the assay. As such, undiluted samples were used for determination of IL-1β,
whereas samples for IL-6 and TNF-α were diluted 20 times over. In all three assays, BRD3731
(GSK3β inhibitor) was the most efficacious counter-inflammatory compound; BRD0320
(GSK3α/β inhibitor) significantly attenuated cytokine secretion as well, whereas BRD0705
(GSK3α inhibitor) only fairly subdued their production. Comparisons drawn between selective
isoform inhibition by BRD0705 (GSK3α inhibitor) and BRD3731 (GSK3β inhibitor) were yet
again statistically meaningful to have occurred by chance.

We then looked into whether blunting of GSK3 activity mediates its pro-curative outcomes
through tuning the nuclear content of NF-κB and Nrf2. Analysis of nuclear lysates from the
relevant treatment groups by western blotting confirmed that GSK3 inhibitors hindered the nuclear
translocation of the p65 subunit of NF-κB and elicited that of Nrf2, echoing the same trend
theretofore identified, where BRD3731 (GSK3β inhibitor) displayed the maximum suppressive
effect for NF-κB and a remarkable Nrf2 mobilizing impetus. Dual isoform inhibition by BRD0320
considerably tempered the proinflammatory NF-κB nuclear accumulation and enhanced the
buildup of the anti-oxidative Nrf2, yet not as effectively as GSK3β-selective inhibition. GSK3αselective inhibition by BRD0705 was yet again only marginally effective at altering the levels of
NF-κB or Nrf2 in the nuclear compartment.
Immunoblots were also prepared for β-catenin to determine the extent to which the compounds
bear upon Wnt/β-catenin signaling. Interestingly, only samples from BRD3731 (GSK3β inhibitor)treated cells gave a chemiluminescent signal; all other groups consistently failed to signal any
discernable nuclear presence of β-catenin. We attribute such an observation to the amount of
protein loaded into the gel, which was capped at 15 μg/well, given the concentration of the samples
and the maximum volume/well of the NuPAGE™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gels
(NuPAGE® Technical Guide General Information and Protocols for Using the NuPAGE®
Electrophoresis System, 2010). However, since BRD3731 (GSK3β inhibitor) is prominently
competent at elevating nuclear β-catenin compared to the other compounds (Wagner et al., 2018),
the levels of the β-catenin protein was high enough to show up on our blots, whereas the levels
from other samples were too scarce to get picked up. Such superb paralog-selective stabilization
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of β-catenin entails that BRD0705 as well as other highly selective inhibitors of GSK3α could
indeed solve clinical failure of GSK3 therapies, which are largely owed to inhibitor promiscuity.

We next aimed to question the mechanistic dependency of the anti-inflammatory effects of GSK3
inhibition on Nrf2/ARE signaling. To that end, we sought to silence Nrf2 mRNAs using a pool of
3 different Nrf2-targeting DsiRNAs. Given the notoriety of macrophages for being difficult-totransfect cells and driven by the fact that reverse transfection is often more conducive to a higher
transfection efficiency, SIM-A9 cells were reverse-transfected. Success of transfection was
verified by microscopical examination of cells transduced with a TYE 563-labeled DsiRNA, where
the transfected cells showed bright orange fluorescence, as opposed to negative controls, which
remained entirely dimmed. Changes to cellular morphology and doubling time were attributed to
the inherent cytotoxicity of the transfecting reagent. With initial qualitative assessment suggesting
an operative transfection protocol, we utilized an HPRT-targeting positive control DsiRNA for a
quantitative determination of transfection efficiency. As suggested by post-transfection qPCR
data, HPRT was silenced by 93.33% in cells transfected with the HPRT-targeting DsiRNA in
comparison to cells transfected with a non-targeting negative control DsiRNA. Upon confirming
the efficiency of our transfection methodology, we proceeded to knockdown Nrf2 using the above
outlined methodology. Quantitation of Nrf2 mRNA by qPCR revealed a silencing efficiency
ranging between 81.39% to 88.47% across the various treatment groups. Moreover, HO-1 and
Osgin1 transcripts were preserved at a basal level across all treatment groups; none of the GSK3
inhibitors could upregulate the ARE genes in any considerable manner, not even BRD3731
(GSK3β inhibitor) or SFN, which signifies that our knockdown carried through to the protein level
and resulted in a transcriptional limitation of its target genes.
Finally, the mRNA expression‡ of iNOS, IL-1β, IL-6, and TNF-α was once again determined by
qPCR to assess the effect of Nrf2 knockdown on the anti-inflammatory activity of the GSK3
inhibitors as conveyed by the downregulation of these markers. As ascertained by the
insignificance of GSK3-mediated functional differences between the DsiNrf2 and DsiNTC groups,
‡

Here, expression was normalized to HPRT instead of GAPDH, since the latter did not maintain a stable level of
expression across all treatment group following transfection. This may be attributed to post-transfection oxidative
changes to GAPDH (Butterfield et al., 2010) on account of Nrf2 knockdown. Moreover, in some instances, small
RNAs have been proven to interfere with housekeeping genes such as GAPDH and β-actin (Sikand et al., 2012).

84

knockdown of Nrf2 was proven non-essential to the anti-inflammatory action of the GSK3
inhibitors. This suggests that true anti-inflammatory effects of Nrf2 can best be observed in
conditions of chronicity, rather than acute stimulation, where NF-κB signaling takes over, and that
whenever in action, is not occurring through direct negative regulation by GSK3.
Collectively, our findings consistently showed that BRD3731 (GSK3β inhibitor) maintained antiinflammatory and anti-oxidative prepotence over BRD0320 (GSK3α/β inhibitor) and BRD0705
(GSK3α inhibitor), the latter being middling at best. From this steady modulatory pattern, we can
derive that GSK3β rather than GSK3α primarily drives inflammatory and pro-oxidative processes,
and its inhibition is thus more therapeutically consequential. As such, treatments selectively
targeting GSK3β (BRD3731) are likely to be of superior medicinal outcome than same-dose
paralog-non-discriminating treatments (BRD0320), where GSK3β is inhibited at a rate that is only
fractional of that achieved by targeted inhibition, at any given concentration. Where the dosing
regimen is unchanged, treatments selectively targeting GSK3α, with no antagonism of GSK3β
whatsoever, produce much milder effects, as proven by our results for BRD0705 (GSK3α
inhibitor).

Notwithstanding the above, and in light of promising reports that recognize a potential remedial
benefit for GSK3α in neurodegenerative/neuroinflammatory pathologies (Draffin et al., 2021;
Dunning et al., 2015; Kaidanovich-Beilin et al., 2009; McAlpine et al., 2015; Phiel et al., 2003; J.
Zhou et al., 2013), targeted inhibition of GSK3α should not be altogether disregarded as a
therapeutic strategy, especially in disease groups of known vulnerability to β-catenin-driven
pathologies, such as cancer. As evidenced by our experiments, GSK3α inhibition – despite the
mediocrity of its effects when compared to GSK3β inhibition – was capable of moderating propathological molecular changes. On the other hand, the superb selectivity of the BRD0705 for
GSK3α combined with its inability to activate β-catenin-mediated transcription unveiled a crucial
cog in the mechanistic machinery under study. Consistent with the literature (Koistinaho et al.,
2011; Ougolkov & Billadeau, 2006) and as outlined in Figure 4.1., β-catenin seems to be more
consequential a player in this loop than was anticipated, whereby its maximal activation by
BRD03731 and absence thereof with BRD0705 coincided with attenuated NF-κB signaling and
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modulation of the inflammatory response in consequence. Such an observation can be corroborated
in BRD3731-treated β-catenin knockouts and constitutes a significant future corollary of this work.

Furthermore, and in keeping with previously acknowledged mechanistic models, it would also
seem that GSK3 exerts its proinflammatory function directly through stimulating NF-κB signaling
(Hoeflich et al., 2000) and promoting the production of proinflammatory molecules (NO, IL-1β,
IL-6, and TNF-α), rather than via Nrf2/ARE signaling. The upregulated inflammatory mediators
then go on to stimulate the upregulation of the microglial surface markers of activation (Avik Roy
et al., 2006; X. Zhou et al., 2005). It would therefore make for a cogent argument to state that while
GSK3 is a mutual modulatory factor linking NF-κB activation and Nrf2 inhibition, its regulatory
effect on the two pathways is not codependent.

Figure 4.1. A schematic outlining the GSK3/Nrf2/NF-κB regulatory model underlying GSK3 inhibition in SIM-A9
microglia, as evinced by findings in this study.
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5. CONCLUSION AND FUTURE PERSPECTIVES

Our data accentuates the significance of the dysregulated GSK3/Nrf2/NF-kB regulatory network
in activated microglial cells and emphasizes the multimodal therapeutic potential of GSK3
inhibition in neurodegenerative diseases. The evidence herein provided suggests that suppression
of GSK3 in activated SIM-A9 cells impart anti-inflammatory and anti-oxidative effects. Moreover,
we present proof that paralog-selectivity of GSK3 inhibition is of utmost consequence to its antiinflammatory and anti-oxidative effects, which were maximal with GSK3β-selective inhibition.
This as stated earlier signifies the functional superiority of GSK3β to GSK3α, at least as far as
anti-inflammatory and anti-oxidative functions are concerned.

Further examination of paralog-distinctive features within the presented regulatory network in
more complex experimental constructs – such as those involving neural organoids and transgenic
animal models – would be particularly beneficial since it affords the phenotypic heterogeneity of
microglia and can better recapitulate the relevant molecular pathophysiological backdrop.
Moreover, results of this study warrants further investigation of the utility of GSK3α-selective
inhibition, especially in experimental set ups that best reiterate the pathophysiological contexts
and disease groups which can benefit from a non GSK3β-targeting treatments.

Working beyond the limitations of simplistic in vitro systems would provide invaluable insights
to the intricate crosstalk between neural subpopulations and offer a more categorical assessment
of the molecular mechanisms that are most clinically relevant, which should render the findings of
a more translational value.
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